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ABSTRACT 
 
The complement system is an important part of human innate immunity. It 
consists of approximately 35 proteins in plasma and on cell membranes. 
Complement is activated via three pathways, alternative, classical or lectin 
pathway, and activation can lead to a formation of lytic membrane attack 
complexes. During the activation complement proteins opsonize the target 
for phagocytosis, enhance inflammatory response and attract phagocytes 
to the site. To protect own structures complement is tightly regulated by 
membrane-bound and fluid phase regulators. The main regulator of the 
alternative pathway in plasma is factor H, while the key regulator of the 
classical pathway is C4BP. The major function of complement is protection 
of the host against microbial evasion. Pathogenic microbes, however, have 
developed multiple mechanisms to escape the complement attack. One 
widely used and obviously effective mechanism is utilization of host fluid 
phase complement regulators factor H, FHL-1, which is a truncated form of 
FH, and C4BP.  
 
In this thesis complement evasion of different kinds of microbes have been 
studied. The Lyme disease causing Borrelia burgdorferi sensu stricto is 
shown to bind factor H and FHL-1 and the main ligand for factor H was 
identified as the outer surface protein E. Acquisition of factor H enhances 
survival of B. burgdorferi sensu stricto in non-immune human serum. Two 
major borreliae species that cause relapsing fever, B. recurrentis and B. 
duttonii, are shown to utilize both factor H and C4BP. Both the regulators 
maintain their functional activity in regulating the complement system on 
the surface of the relapsing fever borreliae. 
 
Also microbes other than bacteria can utilize complement regulators, which 
is shown with the clinically most important pathogenic yeast Candida 
albicans and microfilariae of a parasitic nematode Onchocerca volvulus. 
Despite being frequently a harmless commensal C. albicans causes 
occasionally systemic life threatening infections. O. volvulus is the 
causative agent of river blindness, and 18 million patients are infected with 
this parasite. Both the microbes are shown to specifically bind fluid phase 
complement regulators. O. volvulus microfilariae bind factor H, while C. 
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albicans binds also C4BP and FHL-1. The bound regulators maintain their 
complement regulatory activity on the microbial surface, which results in 
premature termination of the complement activation cascade. The 
microbial interaction sites on the complement regulators were mapped 
using recombinantly expressed deletion mutants.  
 
Taken together, in this thesis, new microbes, representing bacteria, yeast 
and parasites, are shown to utilize soluble complement regulators for 
protection from the antimicrobial effects of the complement system. 
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1 INTRODUCTION 
 
Humans are constantly surrounded by microbes. Microbes can enter the 
human body in numerous ways, for example in food and drink, in inhaled 
air, via wounds and during contacts with other humans. Many microbes are 
able to use vectors for invasion, for example malaria is transmitted by 
mosquitos and Borrelia spirochetes by ticks and lice. Some microbes are 
very active in the invading human body, even through intact skin, like 
cercariae of a blood trematode Schistosoma mansoni do. Microbes that 
infect humans belong to viruses, procaryotic bacteria, eucaryotic fungi and 
parasites. The enormous variety of hostile microbes, starting from a 25 nm 
virus to a 25 meter long tapeworm, is encountering multiple protection 
mechanisms in humans. Intact skin, mucus secreted from the epithelial 
cells, low pH of the gastric juice and bactericidal agents secreted in body 
fluids (e.g. lysozyme in tears) are some physiological barriers, which 
prevent microbes from entering the human body. Humans also maintain so 
called normal microbial flora on skin and several mucosal membranes. 
These commensal microbes can create an environment where the 
pathogens do not survive (e.g. low pH) and compete with the pathogenic 
ones. Some commensals are symbiotic, for example some participate in 
production of vitamin K in the intestine. 
 
More specific protection against micro-organisms is provided by the human 
immune system. The immune system is divided into two different parts; 
the innate immunity and the acquired immunity. The innate immunity 
includes phagocytes (polymorphonuclear neutrophils, macrophages and 
natural killer cells) and the complement (C) system. T-cells, B-cells and 
antibodies are parts of the acquired immunity. The immune response from 
the innate immunity is quick, non-specific and does not require a previous 
contact with the microbe. The acquired immunity, on the other hand, is 
slower in reacting, much more specific and has the ability to remember the 
invader when encountering it again. With these mechanisms humans are 
relatively well equipped for protection against micro-organisms. 
 
The C system consists of fluid phase and membrane bound proteins. C can 
be activated nonspecifically or via antibodies already specifically bound to 
the target. After the initial activation the proteins of the C system co-
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operate in a cascade-like manner and if the activation continues, cytolytic 
membrane-attack complexes (MAC) are formed. During C activation the 
target is also opsonized for phagocytosis. To protect own cells and 
structures the C system is tightly controlled by regulators on membranes 
and in the fluid phase. 
 
Microbes have evolved to circumvent the immune responses of the host in 
many ways. Nonimmunogenic surface structures, antigenic variation, 
secreted enzymes for inactivation of proteins of the immune system and 
several other mechanisms enable some microbes to be pathogenic and 
invasive. One specific mechanism for immune evasion is utilization of host 
molecules. Microbes have been shown to bind, for example, soluble C 
regulators of the host and prevent C-mediated phagocytosis and lysis. In 
this thesis C evasion mechanisms of different microbes have been studied. 
Bacteria, (Borrelia spirochetes causing either Lyme disease or relapsing 
fever), a yeast Candida albicans and a nematode parasite Onchocerca 
volvulus are studied to show that structurally and functionally very 
different pathogenic micro-organisms have evolved to use a similar 
mechanism for their own protection.  
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2 BACKGROUND OF THE COMPLEMENT SYSTEM 
 
2.1 History and overview 
 
The C system is evolutionarily the oldest part of the immune system. 
Components of C have been found in many animal phyla, e.g. reptiles, 
amphibians and bony fishes. A C3/C4 -like protein with an intrinsic activity 
for covalent binding (an internal thioester bond) has been described in 
nonvertebrates, such as ascidians, sea urchins and even arthropods. 
Adaptive immunity, on the other hand, is found only in jawed vertebrates. 
Many C proteins resemble each other. For example C3, C4 and C5 belong 
to the same family. Gene duplications during the evolution have most 
probably been important for the development of C to the functional and 
structural complexity it nowadays presents in humans (222).  
 
The C system in humans was discovered in the 1890's, when Nuttall and 
others discovered a heat-sensitive component in immune human serum. 
This component was found to be essential for the killing of bacteria. The 
name complement for this system was given by Paul Ehrlich in 1899, when 
C was thought to complement antibodies in the target lysis. As early as 
then Ehrlich thought that C consists of a group of factors, which affect 
each other. At that time C was seen only as an effector mechanism for the 
antibodies. Alternative pathway (AP) and the idea of C activation in the 
absence of antibodies was proposed in the 1950’s by Louis Pillemer, who 
originally named AP as the properdin pathway (200).  
 
The C system consists of approximately 35 proteins in plasma and on cell 
surfaces. It is activated via three different pathways, classical pathway 
(CP), lectin pathway (LP) and AP. In the absence of regulation activation of 
any of the three pathways leads to the formation of C3–convertases, 
which enzymatically cleave intact C3 molecules. C3 is cleaved to C3b, 
which binds covalently to targets. If the activation continues, proteins of 
the terminal pathway (TP) form massive MAC. MAC can penetrate the 
target cell membrane and form pores that subsequently lyse the target 
cell. The surface-attached C3b molecules are recognized by C receptors on 
phagocytes, and small peptides (C3a and C5a) cleaved from C3 and C5 
attract macrophages and neutrophiles to the site. Taken together, C can 
    
   
 17 
directly lyse the targets, mark them for phagocytosis and participate in 
generation of an inflammatory response.  
 
2.2 Complement activation pathways 
 
2.2 .1 Alternative pathway  
 
C3 is the central protein of the C system, firstly because of its role in the 
activation, but also by its large amount in the blood. The serum 
concentration of C3 is 0.7-1.5 mg/ml (Table 1). C3 has a molecular weight 
(mw) of 185 kD and it consists of 2 chains, α and β, which are held 
together by one disulphide bond and noncovalent forces (190). Disruption 
of an internal thioester bond in an activated C3 molecule allows it to bind 
covalently to target surfaces.  
 
AP activation starts when the internal thioester bond in C3 is 
spontaneously hydrolyzed in the fluid phase resulting in the formation of 
C3(H2O) (233). Functionally the C3(H2O) form as well as C3b can bind 
factor B (FB) and make it susceptible to a cleavage by factor D (FD) to Ba 
and Bb. FB is a single chain serum glycoprotein. The fluid phase C3-
convertase C3(H2O)Bb can cleave C3-molecules into C3b and C3a. The 
small (9 kD) single chain C3a peptide (144), cleaved from the alpha-chain 
of C3, acts as an anaphylatoxin (318). The activated C3b can bind 
covalently to the surfaces nearby via the thioester bond (191, 288). 
Surface-attached C3b binds FB, which is cleaved by FD, and C3bBb, the AP 
C3-convertase essential for the C3b amplification loop, is formed. Binding 
of FB to C3b needs the presence of Mg2+ ions. AP convertases cleave new 
C3 molecules, and within minutes the system can attach billions of C3b-
molecules to the target surface. Surface-bound C3b can bind C5, which is 
susceptible to a cleavage by C3bBb to C5b and C5a. C5a is another 
anaphylatoxin released to the surrounding environment. C5b attached to 
the surface can bind C6, which initiates the TP activation. 
 
2.2 .2 Classical pathway  
 
The first component of the CP is the C1-complex, which consists of one 
C1q and two C1r and C1s molecules each. C1q is formed of six identical 
    
   
 18 
subunits with a globular domain at one end and an elongated collagen-like 
part at the other end. According to its appearance the structure has been 
visualized as a bunch of tulips. C1q interacts with C1r and C1s via the 
elongated parts and binds to a target via the globular domains. The main 
targets for C1 are Fc-regions of IgG or IgM antibodies (147). C1q can bind 
to the antibodies only when at least two IgGs are attached close to each 
other on the target. Therefore, relatively high surface density of Igs is 
needed for the CP activation. In the absence of antibodies C1q can bind to 
bacterial lipopolysaccharides (LPS), nucleic acids, immune complexes (IC), 
some viruses and C-reactive protein (CRP) resulting in CP activation (154, 
193). Ca2+-ions are needed to assemble the C1–complex together (328). 
When C1q is bound to the target via multiple globular domains, its 
conformation changes allowing C1r to activate C1s, that subsequently 
cleaves C4 and C2 (123).  
 
Table 1 . Properties of the components of the AP, CP and LP. 
 
Component Size (kD) Serum conc. Structural features 
ALL PATHWAYS: 
C3 
 C3b 
  
  C3a 
185  
  175  
    
    9  
500-1200 
(µg/ml) 
 
2 chains 
alpha-chain 115 kD 
beta-chain 75 kD 
single chain 
ALTERNATIVE PATHWAY: 
Factor B 
  Ba 
  Bb 
93  
  33  
  60  
140-400 serine protease 
Factor D 24  1-5  serine protease 
Properdin 2-5x53 25 polymer of 53 kD chains 
 
CLASSICAL PATHWAY: 
C1 
  C1q 
   
  C1r 
  C1s 
780  
  460  
   
  80  
  80  
 
100-180 
 
30-40 
50 
 
hexamer of 73 kD subunits 
serine protease 
serine protease 
C4 
 C4b 
 C4a 
102  
   
200-600 3 chains 
alpha-chain 97 kD 
beta -chain 75 kD 
gamma-chain 33 kD 
C2 102  20-25 single chain 
 
LECTIN PATHWAY:  
MBL 3-6x32 0-5 polymer of 32 kD chains, 
collectin 
MASP-1 100  1-10 serine protease 
MASP-2 76   serine protease 
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C4 consists of three chains kept together by disulphide bonds. Like C3b, it 
has an internal thioester bond which, upon disruption, enables C4b to 
attach covalently to a surface (279). C4 is cleaved at a single point to C4b 
and C4a by C1s. C4a acts as a weak anaphylatoxin (120). C4b is 
hydrolyzed in fluid phase by body fluids or gets covalently attached to a 
surface.  
 
C2 is a single-chain plasma protein. It binds to the target-attached C4b in 
the presence of Mg2+ ions and is thereafter cleaved by C1s to C2b and C2a 
resulting in formation of the classical pathway C3–convertase C4b2a 
(168). C2a contains the catalytic site of this enzyme. Activation now 
continues with a cleavage of C3 in the same manner as in the AP activation 
by the AP-convertase C3bBb. The CP C5-convertase (C3b4b2a) is formed 
when C3b binds to the CP C3-convertase (305). This complex cleaves C5 
resulting in initiation of TP. 
 
2 .2 .3 Lectin pathway activation 
 
LP is the most recently discovered pathway of C (314). Mannan-binding 
lectin (MBL) is the first component of LP. MBL has a C1q-like structure 
that consists of elongated collagenous α-helical parts and globular 
domains. In human serum it is present in different forms with different 
numbers of subunits. MBL binds to N-acetyl-glucosamine containing 
carbohydrates or mannose (267). In the circulation MBL makes complexes 
with MBL-associated serine proteases (MASPs) (199, 309), which can 
cleave C4 and C2. After cleavages of C4 and C2 the activation of the LP is 
similar to the activation of CP. 
 
MBL and MASPs have very low serum concentrations. LP might have a role 
in preventing infections during early childhood, since children with homo- 
or heterozygous mutations of MBL appear to have a slightly increased risk 
for recurrent infections (314).  
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2 .2 .4 Terminal pathway 
 
All three C activation pathways can initiate activation of TP. C5 is the first 
component of TP (Table 2). It consists of two chains linked together with 
one disulphide bond (304). Unlike its close homologues C3 and C4, C5 
does not contain an internal thioester bond (128). CP and AP C5-
convertases cleave C5 into C5a and C5b (62). C5a, a potent anaphylatoxin 
and chemotaxin (59), is released, and C5b binds to C6 (90). Binding of C6 
to C5b has to occur within minutes, otherwise the conformation of C5b 
changes and C6 binding is no longer possible (85). If the association with 
C6 is successful, C7 can bind to the C5b6 complex. The hydrophobic 
complex formed (C5b67) attaches itself to a nearby membrane. The next 
component of the TP, C8, binds to C7 (174) and the complex inserts itself 
deeply into the target membrane. The binding of C9 to C5b678 allows the 
complex to disturb the membrane stability and when more C9 molecules 
are recruited a pore is formed (247). Upon binding to C8 a major 
conformational change takes place in C9 transforming it to an elongated 
molecule that spans across the membrane (312).  
 
Table 2 . Properties of the TP components. 
 
Component Size (kD) Serum conc. 
(µg/ml) 
Structural features 
 
C5 
 C5a 
 C5b 
 
192  
  11  
  181  
 
75  
 
2 chains 
alpha-chain 118 kD 
beta -chain 74 kD 
 
C6 
 
120  
 
45-70 
 
single chain  
 
C7 
 
105 
 
55-60 
 
single-chain  
 
C8 152  80 3 chains 
alpha-chain 65 kD 
beta -chain 65 kD 
gamma-chain 22 kD 
 
C9 
 
70 
   
 
80 
 
single chain  
 
Structurally the TP components C6, C7, C8 and C9 are relatively 
homologous to each other. C6, C7 and C9 are single-chain proteins (86) 
whereas C8 is formed from 3 chains  (88, 89). 
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There are two hypotheses how TP causes cell lysis. One suggests 
formation of a hydrophilic channel through the cell membrane resulting in 
the exchange of small ions and water across the target cell membrane. The 
other hypothesis is based on formation of "leaky patches" on the target 
cell membrane (30, 95).  
 
2.3 Regulation of the C system 
 
As described above, C is potentially a very cytotoxic system. If not 
controlled, a destruction of self structures would follow. Regulators are 
needed to protect own cells and to avoid overconsumption of the C 
components. Most C regulators on the cell membranes and in the fluid 
phase act on C3b or prevent the formation of MAC.  
 
Regulation of C at the C3-level occurs mainly by two different mechanisms. 
First is the enhanced inactivation of C3b and C4b. Serine protease factor I 
(FI) is the enzyme that cleaves C3b and C4b, but it needs a cofactor. 
Thus, many regulators possess a cofactor-activity for FI. The second 
regulatory mechanism at the C3-level is direct interference with an active 
C3-convertase either by binding to it and displacing the enzymatic 
component C2a or Bb, called the decay accelerating activity or by 
prevention of C3-convertase formation. 
 
2.4 Membrane bound regulators  
 
2.4 .1 Complement receptor type 1 (CD35) 
 
Complement receptor type 1 (CR1) is expressed by many circulating cells, 
like erythrocytes, polymorphonuclear leukocytes and lymphocytes (98). It 
is a single-chain glycoprotein with a transmembrane domain (Table 3). 
Most of CR1 in the circulation is found on the surfaces of erythrocytes and 
only trace amounts are found in a soluble form in plasma. CR1 regulates 
both AP and CP by acting as a cofactor in FI-mediated cleavage of C3b and 
C4b and by accelerating the decay of the AP and CP C3-convertases (100, 
145). CR1 is the only regulator which can also act as a cofactor in further 
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cleavage of iC3b into C3c and C3d fragments under physiological 
conditions (205),  
 
CR1, factor H (FH), C4b-binding protein (C4BP), membrane cofactor 
protein (MCP) and decay accelerating factor (DAF) consist of short 
consensus repeat (SCR) domains. SCRs are also called complement control 
protein domains or Sushi repeats. They are encoded by genes in one 
cluster in chromosome 1, called the regulators of the C activation gene 
cluster (RCA) (141). Each globular SCR has approximately 60 amino acids 
held together by two disulphide bonds (169). 
 
CR1 has not only a role in the regulation of C but also in the transport and 
removal of IC and opsonized targets. CR1 on blood cell surfaces binds C3b 
and C4b mediating transport of particles coated with C3b and C4b on 
blood cell surfaces to liver or spleen for degradation. (278). Binding of CR1 
to the collagenous tail of C1q might also play a role in the clearance of ICs 
(171).  
 
2.4 .2 Decay-accelerating factor (CD55) 
 
DAF is a 70 kD transmembrane protein widely expressed on various tissues 
and cells (206). It consists of four SCRs and is attached to a cell surface 
with a glycophosphatidylinositol-anchor (GPI-anchor). DAF was first 
isolated from erythrocytes as a protein capable of accelerating the decay 
of the CP C3-convertase (219). It inhibits both AP and CP C3-convertases 
by displacing Bb from the C3bBb complex and C2a from the C4b2a 
complex (110). The functional site has been located to SCRs 2-4 for the 
AP inactivation and to SCRs 2 and 3 for the CP inactivation (45, 65). 
Soluble forms of DAF have been found in different body fluids (206). 
 
Microbes can exploit DAF in pathogenesis, as DAF has been found to be a 
receptor for many viruses (echoviruses, coxsackieviruses) as well as for 
uropathogenic E. coli strains (192). 
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2.4 .3 Membrane cofactor protein (CD46) 
 
First after its discovery MCP was called glycoprotein (gp) 45-70 due to its 
broad size variation in SDS-PAGE (60). It was soon found that MCP has 
cofactor-activity for FI-mediated cleavage of C3b and C4b (283). Unlike 
DAF, it does not have decay-accelerating activity. MCP is expressed on a 
vast variety of tissues and circulating cells, but not on red blood cells. It is 
expressed as isoforms due to alternative splicing of the gene (249). 
Structurally the protein has a cytoplasmic domain, a transmembrane part 
and four SCRs (195). SCRs 3 and 4 are essential for the function (3). 
There are small amounts of functionally active soluble MCP in serum and 
other body fluids (282). 
 
Some microbes, like measles virus, use MCP as a receptor to facilitate 
entry to nucleated cells. Neisseria gonorrhoeae and N. meningitidis attach 
by their pili to MCP expressed on epithelial cells (192). Some M-proteins of 
group A Streptococcus also seem to mediate adhesion to keratinocytes by 
binding to MCP (115).  
 
Table 3. Properties of the membrane bound inhibitors of C.  
 
Regulator Binds to Structure/size 
 
Function in C 
CR1 (CD35) C3b, C4b, C1q 30 SCRs 
200 kD 
DAA1, CFA2 
DAF (CD55) C3b, C4b 4 SCRs, GPI-anchor 
65 kD 
DAA 
 
MCP (CD46) C3b, C4b 4 SCRs 
60 kD 
CFA 
CD59 C5b-8, C5b-9 Single domain, GPI-
anchor 20 kD 
Prevents 
binding of C9 
to C5b-8 
1 DAA=decay accelerating activity 
2 CFA=cofactor activity 
 
 
 
2.4 .4 Protectin (CD59) 
 
Protectin is the most abundant cell surface regulator of C. It is expressed 
by all circulating cells, endothelial and epithelial cells and in many tissues 
(80, 209). Functionally protectin can bind to the C5b-8 complex and 
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prevent binding of C9 to the complex and block formation of MAC (207, 
271)  
 
CD59 and DAF are both GPI-anchored proteins. Paroxysmal nocturnal 
hemogloninuria (PNH) is a disease caused by a somatic mutation in 
hematopoietic stem cells. The mutation affects synthesis of the GPI-anchor 
and as a result cells without the respective C regulators are found in the 
circulation. This leads to C-mediated lysis of unprotected red blood cells 
and symptoms of PNH (anemia, hemoglobinuria) (220, 232). 
 
2.5 Fluid phase regulators 
 
2.5 .1 C1-inhibitor 
 
C1-inhibitor (C1INH) is a fluid phase regulator of the CP (Table 4). It  
belongs to the serine protease inhibitor -family called serpins (116). C1INH 
inhibits C1 by two mechanisms. First, it binds to the activated C1r and C1s 
molecules and removes them from the C1-complex (330). Secondly, C1INH 
prevents autoactivation of C1 that could occur in the absence of 
activating antibodies (329). C1INH is the only regulator of the C1-
complex, but it acts also in the kinin-kallikreinin system (42).  
 
The importance of C1INH is demonstrated by patients who are deficient in 
C1INH. The deficiency leads to a disease called hereditary angioedema 
(HAE). The main symptom of HAE is edema in the gastrointestinal tract, 
airways and in the skin. Decreased amounts of C1INH or mutations at the 
functionally critical sites cause uncontrolled CP activation and also 
activation of the kinin system. The symptoms are believed to be largely 
due to the release of bradykinin (81). 
 
2 .5 .2 Factor I  
 
FI is a very important serine protease enzyme in the C cascade. It was 
originally named as the C3b inactivator (C3bINA) because it participates in 
the inactivation of C3b. By that time it was already known that FI needs a 
cofactor for its enzymatic function (234, 323). FI cleaves C3b when a 
cofactor FH, CR1 or MCP is present. For the inactivation of C4b FI needs 
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C4b-binding protein (C4BP), CR1 or MCP as a cofactor (215). C3b gets 
cleaved into iC3b by FI at two sites in its α'-chain releasing a small 
fragment called C3f (118). Further FI-mediated cleavage of iC3b occurs 
only when CR1 acts as a cofactor (272). C4b α-chain is cleaved by FI and a 
cofactor at two sites releasing a C4c fragment and leaving C4d to the 
surface. 
 
2.5 .3 Factor H  
 
FH is the most important fluid phase regulator of the AP. Initially it was 
described as β1H -globulin (221) capable of regulating C3 activation 
(234). FH acts at the C3-level by three different mechanisms (323). It is a 
cofactor for FI in the cleavage of C3b, resulting in formation of inactivated 
iC3b (127, 234) . Two cleavages of C3b by FI and FH can occur in vivo, 
and in vitro further cleavages are possible under nonphysiological 
conditions (272) . FH also accelerates a decay of the AP C3-convertase by 
dissociating Bb from the convertase and by competing with FB for binding 
to C3b (320, 323). These functions make FH a very efficient regulator of 
the AP amplification phase. New suggested functions for FH outside the C 
system include mediation of cell adhesion (15, 87)  
 
Structurally FH consists of 20 SCRs (287) (Fig.1). The regulatory site of 
FH for C3b has been located to SRCs 1-4 (119, 184, 186). Other binding 
sites to C3b have been localized to SCRs 12-14 and 19-20 (159, 161, 
285). FH interacts with heparin via three binding sites; one in SCR7 a 
second in SCR 20 and third in SCR9 (32, 33, 227, 231).  
 
Together with C3b FH has an important role in determining whether a 
surface acts as an activator of the AP or not. FH can bind to polyanions 
(like sialic acids and glycosaminoglycans such as heparan sulphate) on 
surfaces. When bound to these negatively charged structures FH has a 
higher affinity for the target-bound C3b (208). Sialic acids have been 
shown to protect a surface and their removal makes the surface an 
activator by inhibiting the decay-accelerating activity of FH (99). On the 
other hand, C3b bound to an activating surface has a decreased affinity 
for FH, which makes the target more susceptible to the AP activation. 
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FH, like its truncated form factor H-like protein (FHL-1) (see below), has 
been shown to be secreted by some tumour cells, such as human 
glioblastoma cells. The secretion and/or binding of FH/FHL-1 increases the 
C resistance of these cells (163).  
 
 
 
 
 
 
 
 
 
 
 
 
A very interesting aspect of FH is its newly discovered role in three 
diseases, like atypical hemolytic syndrome (aHUS), membranoproliferative 
glomerulonephritis (MPGNII) and age-related macular degeneration (AMD).  
 
Atypical HUS is not followed by infection with enterohemorragic E.coli like 
the typical HUS but is a s.c. familial or sporadic disease usually with a 
genetic background. C3 deposition in tissues and decreased amounts of C3 
in the patient sera were found in atypical HUS patients as early as in 1977 
(24). Several different mutations in the FH-coding gene have been 
discovered from aHUS patients. A premature stop-codon in the reading 
frame affects the amount of FH and point mutations alter its function 
(273). Point mutations are clustered in the C-terminus and especially in the 
SCR20 of FH (51, 238, 270). SCR20 is an important interaction site for 
FH, as it contains partially overlapping binding sites for C3b, C3d and 
heparin (132). Thus it is not a surprise that point mutations in FH SCR20 
affect its ability to bind to a surface-bound C3b (196, 276) or surface 
polyanions (230, 240).  
 
Another disease associated with FH deficiency or dysfunction is type II 
MPGNII. In this disease FH in unable to protect the basement membranes in 
Fig. 1. Schematic structure of FH and FHL-1. 
 regulatory site for C3b  
 N C 
binding sites for heparin  
 
other binding sites for C3b 
FH 
FHL-1 
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the kidney glomeruli. As a result, extensive C activation leads to C3b and 
terminal C component depositions that lead to obstructions of the filtering 
function of the basal membranes.  
 
FH deficiency has been described in approximately 12 families. Individuals 
without FH are more prone to MPGNII and bacterial infections, especially by 
Neisseria (213). Pigs deficient in FH have a single nucleotide change, which 
causes a framework shift and blockes secretion of FH (130). FH-deficient 
knock-out mice suffer from MPGNII and extensive deposits of C3b are 
found in the kidney glomeruli (243).  
 
Recently several groups reported that a polymorphism in the gene 
encoding FH is a risk factor for AMD (92, 124), the most common cause of 
blindness in industrialized countries. Increased amounts of deposited C5b-9 
are found in the maculae of the patients with AMD (170). In the risk allele 
a tyrosine at position 402 is SCR7 is converted to histidine. 
 
2.5 .4 Factor-H like protein  
 
FHL-1 is a 42 kD alternatively spliced product of the FH-coding gene (97). 
The protein consists of seven SCRs identical to the N-terminal SCRs of FH 
and an unique tail of four amino acids at the C-terminus (334). FHL-1 has 
one binding site for C3b and can act as a cofactor in FI-mediated cleavage 
of C3b similarily to FH (184). Decay accelerating activity for C3- and C5-
convertases has also been described (186). In addition, FHL-1 has been 
suggested to mediate cell adhesion to a fibronectin matrix (134).  
 
2.5 .5 Factor-H related proteins  
 
Recently several proteins consisting of FH-like SCRs have been described, 
as reviewed in (332). These proteins are transcripts of different genes in a 
same chromosome (1q32) as FH and FHL-1. They share structural 
similarity with FH (Fig. 2), and therefore they are considered to belong to 
one family and are called FH-related proteins (FHRs) (333). Five human 
FHR proteins have been identified in a family and they are named FHR-1 
through FHR-5.  
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FHR-1 consists of 5 SCRs and FHR-2 of 4 SCRs. Both are found in two 
differently glycosylated forms in plasma. The two C-terminal SCRs in all 
FHRs share high homology with the C-terminal SCRs of FH (96, 290, 292). 
FHR-3 and FHR-4 are structurally very similar (289, 291) and they bind to 
C3b, C3d and opsonized pneumococci (133, 135). Physiological functions 
of these proteins are still not known (335). Recombinant FHR-5 binds to 
C3b in vitro (203) and has been detected in glomerular immune complexes 
(214). In rat, FHR-5 homologue inhibits the AP of rat C (268). 
 
Yet another FHR of 63 kD, named FHR4A, was recently described. 
Structurally it is slightly different from the other FHRs, as it has an internal 
duplication of four SCR domains (162). FHR-4B (previous FHR-4) is an 
alternatively spliced product of the FHR-4A gene.  
 
 2.5 .6 C4b-binding protein  
 
The major fluid phase regulator of the CP and LP pathways is C4BP (23). It 
was isolated from mouse and human serum in the 1970's (102, 277).  
 
The appearance of C4BP has been described as spider-like (Fig. 3). It 
consists of 7 or 8 α-chains and one β-chain (76, 77), which are held 
19 20 17 18 15 16 13 14 11 12  9 10  7  8  5  6  3  4  1  2 
 7  5  6  3  4  1  2 
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 2  1 
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FHR-2 
FHR-3 
FHR-4 
FHR-5 
 3 
 4  5  3 
 4  3 
 5  4 
 2  1  3  5  4 
 2  1  7  5  6  3  4  9  8 
Fig. 2. The FH protein family. Numbered circles represent SCR domains and  
the alignment is shown according to highest homology between SCRs. 
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together by disulphide bonds and hydrophobic interactions (166). Like 
other C regulatory proteins of the RCA gene cluster, C4BP consists of 
SCRs. There are eight SCRs in each α-chain and three in the β-chain (57, 
58, 139). C4BP circulates in plasma in a complex with protein S (73). 
Vitamin K-dependent protein S is bound to the β-chain via SCR1 (74, 75, 
125). A reason for complex formation between protein S and C4BP is not 
well understood. C4BP-bound protein S is not active in its anticoagulant 
function. Localization of C4BP via protein S to negatively charged surfaces 
(281) or to apoptotic cells (319) has been proposed as a physiological 
function. Interestingly, C4BP bound to apoptotic cells in complex with 
protein S inhibits phagocytosis of these cells (167). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C4BP binds to its major ligand, C4b, via α-chains (137). Only four α-chains 
can bind simultaneously to C4b molecules on one surface, probably 
because of sterical hindrance (331). N-terminal SCRs 1-2 and a cluster of 
positively charged amino-acids mediate binding of C4BP to C4b (39, 40). 
The binding site for C4BP in C4b is in the α-chain (136). When bound to 
C4b, C4BP acts as a cofactor for FI-mediated cleavage of C4b (111, 112) 
ß-chain 
binding site for C4b and heparin 
SCR of the α-chain 
Group A Streptococcus 
Bordetella pertussis 
Neisseria gonorrhoeae 
 
Moraxella catarrhalis 
Fig. 3. Schematic structure and microbial interaction sites in C4BP 
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and accelerates the decay of the CP C3-convertase C4b2a (109). C4BP 
can also participate in regulation of the AP. At high concentrations 
(approximately 1000x higher when compared to FH) C4BP can accelerate 
the decay of the AP C-convertase C3bBb (36).  
 
2 .5 .7 S-protein (vitronectin) 
 
Fluid phase regulators of the terminal pathway prevent the attachment of 
C5b67 to the target membrane or prevent the binding of C9 to the C5b-8 
complex. The short life-time of the C5b67 complex is a control mechanism 
in itself. If the complex does not bind first the membrane and then C8 
within a few hundreds of milliseconds the C5b67 complex is unable to bind 
C9 and the TP activation stops (218).  
 
Vitronectin and S-protein were described by two different groups and thus 
originally named differently (22, 248) . Later structural and functional 
studies showed that the two proteins were the same (251). S-protein is a 
fluid-phase protein in plasma and in a variety of body fluids (284).  
 
In the C system S-protein acts as an inhibitor of MAC formation by binding 
to the soluble C5b67-complex and preventing the attachment of the 
complex to a membrane (248). Binding of S-protein to C5b-7 does not 
inhibit subsequent binding of C8 and C9, but the end result is a soluble 
SC5b-9, which is not able to cause lytic holes to the membrane. Other, not 
C-related, functions for S-protein are multiple. It has been shown, for 
example, to mediate of cell adhesion to tissues (129) and regulate heparin-
mediated anticoagulation (252). 
 
2.5 .8 Clusterin 
 
Clusterin (SP-40,40) is a protein with many names and proposed functions. 
It is heavily glycosylated protein and has two chains, α and β, held together 
by disulphide bonds (313). Multiple functions of clusterin include clearing 
of cell debris and lipid transport (152). Clusterin is present in serum and 
other body fluids.  
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In the C system clusterin, similarily to S-protein, binds to the C5b-7 
complex and prevents its attachment to cell surfaces (56). It can bind to 
C7, C8 and C9 (311), but the role of clusterin in the regulation of MAC is 
still uncertain.  
 
Table 4. Properties of the fluid phase C inhibitors. 
 
Regulator Binds to Structure/size  
(kD) 
 
Function  Serum 
conc. 
(µg/ml) 
C1 inhibitor  
(C1INH) 
C1r 
C1s 
serine protease 
inhibitor/71  
dissociation of C1r, 
C1s from C1q 
inhibition of C1r, 
C1s 
200-250  
Factor I 
(FI) 
C3b 
C4b 
Serine protease 
/90  
 
Cleaves C3b and 
C4b; needs a 
cofactor 
30-40  
Factor H 
(FH) 
C3b Single chain with 20 
SCRs/150  
DAA1, CFA2  450  
C4b-binding 
protein 
(C4BP) 
C4b 7-8 α-chains of 8 
SCRs, 1 β-chain with 
4 SCRs 
/540-590  
DAA, CFA 150-170  
S-protein 
(vitronectin) 
TCC3 n x 77  Inhibits binding of 
C5b-7 to membrane 
250-540  
Clusterin C5b7 Dimer with α and β 
chains/70   
Inhibits binding of 
C5b-7 to membrane 
250-420  
1 DAA=decay accelerating activity 
2 CFA=cofactor activity 
3 TCC=terminal C complexes (C5b-7, C5b-8, C5b-9) 
 
 
2.5 .9 Properdin 
 
Properdin is the only known positive regulator of C. It binds to the AP C3-
convertase C3bBb and increases its life span and activity (101, 204). 
Properdin is a fluid phase protein with a serum concentration of 
approximately 25 µg/ml. Properdin-deficient individuals suffer from 
bacterial, especially meningococcal, infections (61).  
 
2.6 Functions of the complement system 
 
One major function of the C system is protection against invading micro-
organisms and there are several mechanisms to achieve this. First, 
opsonization is an important consequence of the C activation. C4b, C3b 
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and its cleavage fragment iC3b attached to a surface are recognized by 
specific C-receptors (CR1 and CR3) on phagocytic cells. Binding of the 
target to phagocytes is a prerequisite for its phagocytosis and killing. 
Second, MAC-complexes formed during the TP activation can directly lyse 
the target cells such as invading microbes. Third, anaphylatoxins C3a and 
C5a are cleaved from C3 and C5 during C activation and have two roles in 
enhancing the inflammatory reaction. Both C3a and C5a act as 
anaphylatoxins. For example, binding of C3a to its receptor on mast cells 
and basophils triggers degranulation of the cells and subsequently 
increases vascular permeability and facilitates cell trafficking (72). 
Phagocytes are attracted to the site by chemoattractive C5a and are 
activated via binding of C5a and C3a to their receptors (321).  
 
Fourthly, C3a and its carboxypeptidase cleaved inactivated form, C3a-
desArg, have recently been shown to act as antimicrobial peptides against 
Gram-negative and Gram-positive bacteria by breaking bacterial 
membranes (223). The fifth antimicrobial role for C is actually a link 
between the C system and the adaptive immunity. C3d is able to act as a 
potent molecular adjuvant in antibody production. When attached to an 
antigen C3d and especially multiple C3d molecules enhance the acquired 
immune response by B cells (82) and affect also the amount and repertoire 
of IgM (53). 
 
Clearing of immune complexes (IC) and debris from the human body is 
another important function of the C system (278). ICs are formed when 
antigens and antibodies are aggregated together in the human body. These 
complexes activate the C system, which leads to opsonization. CR1-
receptors on erythrocytes regocnize C3b and C4b and transfer the 
complexes to liver or spleen for degradation.  
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3 MECHANISMS OF MICROBIAL COMPLEMENT EVASION  
 
The C system can be activated efficiently on a foreign or nonprotected 
target and the main results of a successful activation are opsonization for 
phagocytosis and lysis of the target cell. In a general, microbes are 
susceptible to C activation. There are numerous microbes which are able to 
multiply in the human host and cause diseases despite of the activities of 
the C system. Many mechanisms have evolved in microbes for C evasion 
and probably their ensure survival by using more than one. As an example, 
the blood trematode Schistosoma mansoni has been described to possess 
nine different C evasion strategies (326). Microbial C evasion is a very 
complex subject, and new observations will eventually increase our 
understanding of the ingenious mechanisms the pathogenic microbes have 
for their survival. Excellent reviews of the subject have recently been 
published (34, 160, 326).  
 
Some general C evasion mechanisms of microbes are discussed in this 
chapter. Utilization of fluid phase regulators FH, FHL-1 and C4BP are 
discussed in more detail. 
 
3.1 Microbial surface structures  
 
Physical barriers, like capsule and outer membrane of bacteria or tegument 
of parasites, like S. mansoni, protect the microbes from a damage caused 
by antimicrobial proteins of the host. In Staphylococcus aureus the 
expression of capsular polysaccharides enhances survival from 
opsonophagocytosis (307). Long surface molecules and dense capsular 
structures can sterically hinder the attachment of C proteins to the 
surface (325) or participate in the release of TCC (158). Salmonella 
montevideo binds preferentially C3b via long polysaccharide side chains of 
LPS. As a consequence, C becomes activated more remotely from the cell 
membrane disabling membrane insertion of the C5b-9-complex (157). 
 
Sialic acids or glycoproteins on the microbial surface can impede the 
recognition and activation of C. Trypanosoma cruzi has a very active trans-
sialidase enzyme on its surface. Sialylation of the surface is rapid and 
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protects T. cruzi from C attack. This is probably mediated by acquisition of 
the host FH to the sialylated surface (310).  
 
3.2 Shedding and degradation of C components  
 
The removal of surface bound C components can prevent harmful effects 
of C activation. Promastigotes of Leishmania major prevent formation of 
MAC by releasing C5b-9-complexes to the surroundings (254), and 
promastigotes of L. donovani can release 50% of bound C3b within 30 
minutes by a proteolytic cleavage (255). Secreted proteolytic enzymes 
can degrade C components. For example, secreted proteases of S. mansoni 
schistosomula can cleave C3b (197) and other surface-attached host 
proteins and make the parasites resistant to the AP attack (198). 
Streptococcus pyogenes inactivates chemotactic activity of the 
anaphylatoxin C5a by an enzymatic cleavage (322). Candida albicans 
proteinases have been suggested to degrade C3b and thus disable AP 
activation (164).  
 
3.3 Microbial C inhibitors 
 
Microbial C inhibiting proteins have been described in bacteria, parasites 
and viruses. Glycoprotein C (gC) of herpes simplex virus 1 is expressed on 
the surface of the virus-infected cells and can bind C3b and iC3b. After 
binding to C3b gC blocks the interaction between C3b and properdin and 
accelerates the decay of C3bBb. These functions have also been detected 
with purified gC (108, 175). In a murine model of herpes infection the 
viruses that lacked the functional domain of gC were less infective (194).  
 
Molecular mimicry of C proteins is a very special mechanisms for C evasion 
by microbes. Trypanosoma cruzi gp160 protein is anchored to the surface 
of T. cruzi trypomastigotes via a GPI-anchor and is able to accelerate 
decay of the AP C3-convertase. At the DNA-level the sequence coding for 
gp160 is 60% homologous to a gene encoding DAF (225, 236). Cells 
infected with vaccinia-viruses secrete vaccinia virus C-control protein 
(VCP), which is capable of inhibiting the CP. VCP contains four SCRs and 
the sequence similarity to the SCRs 1-4 of the C4BP α-chain is 38% (178). 
Mutated vaccinia viruses without VCP are less infective in an animal model 
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(146). Herpesvirus saimiri has a homologue of CD59, which can bind to 
MAC and inhibit C9 polymerization and lytic effects of MAC (8, 9). 
 
Candida albicans hyphal forms have been reported to have two proteins 
that are functionally similar to human CR2-like and a CR3 -like proteins. 
These surface proteins are suggested to bind C3d or iC3b in a manner that 
inhibits opsonization and phagocytosis (50, 117, 131).  
 
Paramyosin of S. mansoni binds C1q, the first component of the CP. As a 
result the activity of C1q in CP activation is inhibited (188). Paramyosin in 
schistosomes is a multifunctional regulator of the C, as it can also bind to 
C8 and C9 in such a manner that TP activation is stopped (83). This 
inhibitory protein of S. mansoni has been suggested to resemble human 
CD59 both structurally and functionally (235). 
 
3.4 Utilization of host cell surface C regulators 
 
Microbes, especially viruses, can alter the expression of host proteins. 
Cytomegalovirus-infected cells express higher amounts of the C regulators 
MCP and DAF on their surfaces, when compared to noninfected cells (294). 
Viruses can also acquire C regulators to their surfaces when budding out 
from the host cell (316). 
 
Some encapsulated strains of E. coli and Helicobacter pylori are able to 
acquire GPI-anchored CD59 from host cells. "Hijacked" CD59 inhibits 
formation of C5b-9 on the surface of the bacteria and increases their 
survival in serum (265, 266). DAF, another GPI-anchored regulator on the 
cell surfaces, has been shown to be acquired by S. mansoni. DAF on the 
microbial surface can regulate AP activation (236).  
 
3.5 Utilization of fluid phase regulators 
 
3.5 .1 FH and FHL-1 
 
S. pyogenes (group A streptococcus; GAS) is a Gram-positive bacterium. It 
can cause, for example, throat infections, scarlet fever and severe invasive 
infections, such as cellulitis and septicaemia. The major virulence factors of 
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GAS are hyaluronic capsule and M-proteins. M-proteins are fibrillar proteins 
with alpha-helical coiled-coil structures (242). There are more than 100 
different M-serotypes recognized by antigenicity or sequence of the N-
terminal hypervariable region of the M-proteins (103). GAS was the first 
microbe that was shown to bind FH. The ligand for FH was identified as M-
protein. M-protein had been reported to be important in preventing 
opsonization and phagocytosis of GAS (241). Later it was shown that 
strains which bind FH are in general more resistant to opsonophagocytosis.  
 
The first FH-binding site in M-protein (serotype 6) was mapped to the 
conserved C-repeat region at the C-terminus of the protein (31, 105), 
while later the binding site turned out to be in the N-terminal hypervariable 
region (155). The binding site of FH for M-proteins was first located to 
SCRs 6-10 (286). Later, the binding site was narrowed to SCR7 (177) and 
inhibition of the interaction by heparin was shown (31). Thus, it seemed 
that the binding site of FH for M-protein is near to or overlapping with the 
heparin-binding site in the SCR7, and the binding sites for M-protein and 
heparin were localized to the same positively charged region in SCR7 
(114). 
 
M5-protein of GAS binds also another AP regulator, FHL-1, and even with a 
higher affinity than FH (177). In two different M-proteins studied, M5 and 
M6, the hypervariable regions were responsible for binding of FHL-1 (155).  
 
The existence of a second ligand or binding region in M-protein for FH was 
suggested, when a GAS strain expressing a mutant M6-protein lacking the 
FH-binding domain was resistant to phagocytosis (239). The importance of 
M-proteins in the resistance of GAS to phagocytosis was further 
questioned, when a strain expressing a M5-mutant protein incapable of 
binding FH and FHL-1 was as resistant to phagocytosis as a strain carrying 
a full length M-protein (176). However, a second ligand for FH and FHL-1 in 
GAS was identified and turned out to be a fibronectin-binding protein (Fba) 
(228). FH and FHL-1 bind to Fba via SCR7. Interestingly, binding of FHL-1 
to the Fba -protein increases invasion of S. pyogenes to epithelial cells 
(229).  
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Pneumococci (Streptococcus pneumoniae) are common human pathogens. 
They can cause invasive infections like septicaemia, meningitis and 
pneumonia, especially in children and elderly people. The major virulence 
factor of pneumococci is a capsule; the lethal dose of encapsulated strains 
can be up to 50% higher when compared to strains without the capsule 
(13). Serotyping (up to 80 different types) of pneumococci is based on 
polysaccharides of the capsule. Evasion of C is important for pneumococci 
to prevent opsonization. As they are Gram-positive bacteria, MAC is unable 
to penetrate the peptidoglycan and lyse the bacteria. One mechanism for C 
evasion in pneumococci is binding of FH. Neeleman showed that FH binds 
to encapsulated type 3 pneumococci, possibly via a surface-exposed 
protein (217). Later, PspC locus encoded proteins Hic and PspC were 
shown to bind FH via homologous N-terminal regions (78, 148). SCRs 13-
15 (91) and 8-11 (150) of FH were reported to bind to PspC of a 
serotype 2 and Hic of serotype 3, respectively. Later, the first binding site 
was located to SCRs 12-14 with the serotype 3 Hic -protein (149). Thus, a 
new microbial binding site in FH was discovered, as GAS bound FH only via 
SCR7. Recently, another binding site on FH for PspC (serotype 2) was 
mapped to SCRs 6-10 (79). Further evidence of the importance of C 
avoidance for streptococci was obtained when group B streptococci were 
reported to bind FH via β-protein (14). Two different binding sites on FH 
were found (149).  
 
Neisseria gonorrhoeae (gonococcus) is a Gram-negative noncapsulated 
bacterium that causes the sexually transmitted disease gonorrhoea. 
Another bacterium from the same family, N. meningitidis (meningococcus), 
causes meningitis and septicemia. (269). Gonococci can be lysed by MAC. 
Thus, it is very important for pathogenic strains to avoid C. Nonsialylated 
strains of gonococci are serum-sensitive while sialylation of lipo-
oligosaccharides (LOS) makes gonococci resistant to serum. One reason 
for the detected serum resistance is binding of FH. Sialic acids of LOS or 
the loop 5 of the outer surface porin 1A can bind FH (260, 261). N. 
meningitidis, in contrast to N. gonorrhoeae, is usually capsulated, and the 
capsulated strains are more virulent. It has been suggested that the 
capsular polysaccharides inhibit formation of MAC and in the noncapsulated 
strains sialylation might participate in serum resistance by binding of FH 
(259).  
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Parasites are multicellular organisms and obviously the pathogens that live 
for a long time in contact with plasma and are resistant to C mediated cell 
lysis and also well protected against phagocytosis. Echinococcus 
granulosus was the first parasite shown to bind FH as an immune evasion 
mechanism. E. granulosus is a cestode parasite, which forms slowly 
growing hydatid cysts to organs of the host. Cysts are surrounded by a 
two-layer wall and filled with hydatid cyst fluid. When cofactor activity of 
the cyst fluid for the cleavage of bovine C3b was analyzed, it was found 
that the cofactor activity was due to the host FH inside the cyst fluid 
(84), which may have been transported there. 
 
Viruses can obtain membrane C regulators from the host cell surfaces upon 
budding, but they can also benefit from the host fluid phase regulators. 
The human immunodeficiency virus (HIV) has been suggested to bind FH 
by a gp41 protein (301). The binding of FH to virions or virus-infected 
cells could increase the cleavage of C3b to opsonizing fragments iC3b and 
C3d, which might lead to improved uptake of viruses into the C-receptor 
carrying CD4+ T-cells (300). 
 
3.5 .2 C4BP 
 
GAS is thus far the best example of how bacteria need multiple 
mechanisms to evade C. In addition to FH acquisition they can bind C4BP. 
The multiple mechanisms are a further argument for the importance of C 
evasion. Structurally homologous proteins of the M-protein family mediate 
binding of C4BP (308) through the highly variable N-terminal region (156, 
212). In C4BP, the binding sites for GAS and C4b are overlapping but not 
identical (2, 35). Binding of C4BP is beneficial for GAS, as it significantly 
increases the resistance of bacteria to phagocytosis (27, 52). In the M18 
serotype of S. pyogenes another molecule resembling M-protein, Enn18, 
has recently been shown to be a ligand for C4BP (237).  
 
Bordetella pertussis, the causative agent of whooping cough, and other 
members of the family Bordetella, were the second type of bacteria shown 
to bind human C4BP. Mutant strains of B. pertussis and comparison of the 
outer surface proteins of different strains showed that one potential ligand 
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for C4BP is a filamentous hemagglutinin (FHA). FHA is encoded by a single 
gene locus bvg, and mutants lacking the whole locus were negative for 
binding of C4BP. However, FHA-negative mutants still bound some C4BP. 
These findings could be explained by an existence of another ligand for 
C4BP on B. pertussis (26). SCRs 1-2 in C4BP, the binding site for C4b, are 
involved in binding of C4BP to B. pertussis (28). 
 
Gonococci and meningococci are able to acquire both FH and C4BP for 
protection against C. Porins, which bind FH (260), can also bind C4BP 
(151, 258). Identification of another C4BP-binding structure on N. 
gonorrhoeae, type IV pili, indicates the importance of C evasion for 
gonococci (38). When binding of C4BP to gonococci (serotypes Por1A and 
Por1B) was inhibited, the bacteria changed their serotypes from serum 
resistant to serum sensitive in 30 minutes (257).  
 
Escherichia coli is the most common commensal in the intestine. In 
addition, it can cause infections, for example, in the urinary tract. 
Enteropathogenic strains of E. coli cause severe diarrhea and enteritis. 
Septicemias caused by E. coli are found mostly in neonates and usually the 
serotype causing the disease is K1. E. coli has several virulence 
mechanisms. One is the capsular polysaccharide (like K1) and the other, 
the expression of outer surface protein A (OmpA). OmpA-negative bacteria 
are serum-sensitive and OmpA-positive are resistant to serum. Binding of 
C4BP to OmpA of E. coli K1 has been shown to contribute to its serum 
resistance (250).  
 
Moraxella catarrhalis is a Gram-negative coccus. It can be part of the 
normal upper respiratory tract flora, but it is also a causative agent of 
otitis media and sinusitis. M. catarrhalis binds C4BP via two different 
ligands, ubiquitous surface proteins A1 (UspA1) and A2 (UspA2)(224). 
Unlike with the other microbes studied, multiple SCRs (2, 5, 7) of C4BP are 
involved in the interaction. 
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4 OVERVIEW OF MICROBES EXAMINED IN THIS STUDY 
 
4.1 Borrelia burgdorferi sensu lato 
 
There are two different groups of human pathogens in the genus of 
Borrelia; borrelia causing Lyme disease and those causing relapsing fever 
(will be discussed later). The Lyme disease borreliae belong to the complex 
B. burgdorferi sensu lato, which contains 11 different genospecies. Human 
pathogens in the complex are B. garinii, B. afzelii and B. burgdorferi sensu 
stricto. Lyme disease and its causative agent were first described as late 
as 1982 (46). Lyme disease borreliae are transmitted by hard-shelled ticks 
from the Ixodes-family. B. burgdorferi s.s. is the only human pathogenic 
genospecies found in North-America, while all three exist in Europe (94). 
Human beings are not the only hosts for borrelia, as other mammals, birds 
and reptiles can also be reservoir hosts. Ticks are infected by borrelia 
during a blood meal from an infected host. First, the spirochetes reside 
inside the midgut of the tick. Later they move to salivary glands from 
where they are transferred to the next "lunch restaurant" of the tick.  
 
The outer membrane of spirochetes is unique. There is no LPS and the 
number and amount of transmembrane proteins are low. On the other 
hand, the amount of lipoproteins (proteins attached to the membrane via a 
lipid-tail) is high (29, 66). Between the outer membrane and the 
cytoplasmic membrane is a periplasmic space, where flagellas of borreliae 
are attached to either pole of the inner membrane. The expression of the 
outer surface proteins is dependent on temperature, pH, nutritional status 
and several other factors (262, 298). By being able to change the 
composition of its outer membrane borreliae can adapt to the different 
hosts in its life cycle. Some outer membrane proteins are important 
virulence factors. Decorin and fibronectin binding proteins have been 
suggested to mediate adherence to tissues (66).  
 
Lyme disease, called also Lyme borreliosis, is a systemic inflammatory 
disease. Symptoms of Lyme disease vary according to the causative agent 
and geography. Thus, symptoms caused by B. burgdorferi are different in 
North-America and Europe. Infection usually starts as an erythema migrans 
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(EM) lesion (296), which is the most common clinical manifestation of 
borreliosis. EM develops to a site of the tick bite in about 50% of cases 
and is a typical ring-like rash. All three genospecies can cause EM. In a 
chronic phase the skin involvement is called acrodermatits chronica 
atrophicans (ACA). The majority of the ACA cases in Europe are caused by 
B. afzelii. After initial exposure the spirochetes first reside in the skin but 
are later transferred via circulation to different organs. In the late stages 
of infection the most affected sites are the nervous system and joints. 
Arthritis is the major manifestation of borreliosis in North America (295).  
 
Major differences in the serum sensitivity between the strains of Borrelia 
have been reported (43, 172). B. garinii is serum sensitive, while B. 
burgdorferi s. s. and B. afzelii are partially or totally serum resistant. Serum 
sensitive strains are killed in normal human serum (NHS) mostly by the AP 
of C (44, 187, 315).  
 
4.2 Relapsing fever borreliae 
 
Relapsing fever (RF) Borreliae are divided into two groups of spirochetes 
on the basis on vectors. B. recurrentis is the only known borrelia 
transmitted via body or head lice. It causes louse-borne relapsing fever 
(LBRF), also called epidemic relapsing fever. As the name of the disease 
implies, LBRF has the potential to cause epidemics. For example during the 
World War II millions of people were infected in Southern Europe. Nowadays 
LBRF is found in various parts of Africa, for example in Ethiopia (302), and 
in China and Peru. It was only recently when in vitro cultivation of B. 
recurrentis and characterization of the species was accomplished (69, 70). 
Tick-borne relapsing fever (TBRF) is caused by at least 15 species of 
Borrelia, and the disease has a scattered world-wide distribution. Vectors 
for TBRF-borrelia are soft-bodied ticks from the genus Ornithodorus.  
 
Transmission of RF occurs when spirochetes enter blood circulation from 
the site of a tick or louse bite wound. A massive spirochetemia follows. 
The first septic episode ends upon development of antibodies, but because 
the spirochetes are able to change their variable outer surface proteins, 
the spirochetemia returns causing one or more fever relapses. Relapsing 
fever is clinically a severe disease, and its mortality is 30-70% without 
antimicrobial treatment (68).  
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One of the major mechanisms enabling survival of relapsing fever Borrelia 
in a human host is antigenic variation. B. hermsii is the best studied 
example of the antigenic variation. By changing its main antigens on the 
outer membrane a single strain of B. hermsii can form up to 24 different 
serotypes in vivo (299). Two plasmid-encoded major proteins, variable 
large protein (Vlp) and small protein (Vsp), are responsible for the 
antigenic variation (17-19, 21). At the genome level there are four 
mechanisms behind the antigenic variation: (i) modification of transcript 
levels, (ii) gene conversion, (iii) DNA rearrangement and (iv) multiple point 
mutations (for review see reference (20)). In B. turicatae four different 
serotypes have been recognized to exist due to antigenic variation (264). 
It is probable that all relapsing fever borreliae share the same antigenic 
variation scheme as the two species described above.  
 
Relapsing fever borreliae are able to persist blood for long periods. 
Structurally they are probably fairly similar to Lyme disease borrelia. 
Protection against AP and CP is obviously essential for the pathogenicity of 
relapsing fever borreliae. 
 
4.3 Candida albicans 
 
Candida albicans is the yeast that is most often found in human infections 
(25). It belongs to the genera Candidaea, which contains more than 100 
species. Other important Candida species found in human infections are, 
for example, C. tropicalis, C. glabrata, C. parapsilosis and C. kruzei. The 
majority of the members of the genus are plant or animal pathogens. C. 
albicans is the one exceptional species of the genus that is able to grow as 
a cellular, pseudohyphal and hyphal form. This phenomenon, called 
morphogenesis, is reversible and has been considered important for the 
pathogenesis of C. albicans (67). Transformation from a cellular to 
pseudohyphal or hyphal form is dependent on the temperature, pH and 
nutritional conditions on the surroundings.  
 
Most often C. albicans is a harmless commensal on the skin, oral cavity or 
urogenital and gastrointestinal tracts in healthy human beings. In 
immunocompromised patients, like granulocytopenic or lymphopenic 
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patients, C. albicans tends to cause local or systemic infections (104). 
Disseminated C. albicans infections are often lethal due to problems in 
early diagnosis and worsening condition of immunocompromised patients 
(93).  
 
In addition to morphogenesis C. albicans has several other virulence 
factors. It expresses adhesion molecules on its surface. Adhesion of the 
yeast to proteins of extracellular matrix of the host, such as fibronectin 
and laminin, enhances its pathogenicity (49). Several secreted aspartyl 
proteinases (216) and phospholipases have been recognized from C. 
albicans (41), and these enzymes can degrade many host molecules.  
 
The C system has been shown to participate in immune defence against C. 
albicans. Complement deficient guinea pigs have severe invasive C. albicans 
infections with higher mortality than normal animals (113). In addition, an 
efficient C opsonization on the fungal surface is needed for effective 
clearance of Candida by antibodies (54). C. albicans activates to some 
extent all three pathways of C (179). AP is activated via attachment of 
C3b molecules directly to the surface antigens (180). Mannan is one of the 
major component on the outer surface of candida and acts as a ligand for 
MBL, which activates LP (303). Mannan-specific IgG antibodies are found in 
approximately 70% of healthy individuals (1), and by binding to the yeast 
they can activate the CP of complement.  
 
4.3 Onchocerca volvulus 
 
Man is the only known host for the filarial parasite O. volvulus, which is 
transmitted by Simulium black flies. During a blood meal of an infected fly, 
larvae of O. volvulus are transmitted to a subcutaneous tissue of the 
future host. The larvae develop to adult worms in approximately 30 days. 
The adult worms (males measuring 2-4 cm, females 70 cm) live in 
subcutaneous nodules encapsulated by the host for up to 15 years. 
Females release thousands of live microfilariae (mf) daily. Mf reside mainly 
in the subepidermis of the skin and in the eyes (165). Eventually mf are 
transmitted back to a Simulium –fly and the life cycle of the parasite 
continues.  
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Onchocerciasis (also called river blindness) is found in Africa, Latin America 
and the Arabian Peninsula (48). Almost 18 million people are infected with 
the parasite (324). The disease is mainly caused by the immunological 
responses of the host to the wandering mf. Inflammatory reactions lead to 
blindness, skin alterations and muscoskeletal disorders. Ivermectin is an 
effective drug against microfilariae, but not against the adult worms. 
Patients treated once a year with ivermectin are symptomless. Several 
ivermectin-treatment trials have been successful in eliminating the 
symptoms of the river blindness in the endemic areas, but eradication of 
onchocerciasis is still far in the future (47, 71). 
 
Studies on O. volvulus are difficult because there is no animal model 
available and the parasites can not be grown in vitro. Therefore the only 
material is from infected individuals. Studies with mf from other species 
have shown, that opsonization by C together with antibodies are needed 
for phagocytosis (4, 244, 263). In vitro studies with O. volvulus have 
shown, that NHS increases eosinophil-mediated killing of the mf (121). 
How the mf evade C attack in blood is not known. 
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5 AIMS OF THIS STUDY 
 
The general aim of this study was to analyze if different pathogenic 
microbes can utilize the host fluid phase C regulators FH, FHL-1 and C4BP 
for C evasion.  
 
The more detailed aims were: 
 
• To assay if different genospecies of the complex Borrelia 
burgdorferi sensu lato can bind the AP regulator FH and to identify 
the ligand for FH 
• To study if the relapsing fever Borrelia acquire host FH and C4BP  
• To study if nonbacterial human pathogens, pathogenic yeast and 
even a multicellular nematode O. volvulus, can interact with soluble 
host C regulators  
• To test functional activity of host regulators on different microbial 
surfaces and therefore to assess the importance of the interaction 
for pathogenicity of the microbes 
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6 MATERIAL AND METHODS 
 
6.1 Materials 
 
6.1 .1 Sera and cells 
 
Normal human serum (NHS) samples were obtained from healthy laboratory 
personnel (I, II, V) or from a blood bank (University Clinics of Friedrich 
Schiller University, Jena, Germany) (III, IV). Sera were stored at –70°C prior 
to use. C was inactivated from the serum either by adding 
ethylenediaminetetraacetic acid (EDTA) to a final concentration of 10 mM 
(NHS-EDTA) or by heat inactivation at +56°C for 30 min for (NHS-HI). NHS 
was depleted of C4BP (NHS-C4BP) by absorption with anti-C4BP Sepharose 
(319). Normal mouse serum was obtained from BALB/c laboratory mice 
and stored at -20°C. Human umbilical vein endothelial cells (HUVEC) were 
purchased from ATCC (Vanassas, VA, USA) and cultured according to 
standard cell culture procedures. 
 
6.1 .2 Chemicals, plastic materials and buffers 
 
Bovine serum albumin (BSA), trypsin, soybean trypsin inhibitor, inulin, 
Calcofluor-stain, BSK-H and BSK-H Complete media were from Sigma, St. 
Louis, MO, USA. RPMI1640 medium, DMEM medium, L-glutamine, HEPES, 
penicillin and streptomycin were from Gibco, Karlsruhe, Germany. Saboraud 
agar was from Biokar, Diffchamb, Gothenburg, Sweden and heparin from 
Lövens Kemiske Fabrik, Ballerup, Denmark. MaxiSorp microtiter plates were 
manufactured by Nalge Nunc, New York, NY, USA and the C3a Enzyme 
Immunoassay Kit by Quidel Corp., San Diego, CA, USA. The reagents for 
the surface plasmon resonance technique, 0.2 M N-ethyl-N’-(dimethyl-
aminopropyl)-carbodiimide and 0.05 M N-hydroxysuccinimide were from 
Biacore AB, Uppsala, Sweden. The BCA Protein Assay was from Pierce 
Chemical Company, Rockford, IL, USA.  
 
The buffers used were: phosphate buffered saline (PBS; 0.135 M NaCl, 15 
mM phosphate, pH 7.4), PBS with 0.05% Tween, veronal buffered saline 
(VBS; 135 mM NaCl, 3.3 mM diethyl barbiturate, pH 7.3-7.5), GVBS (VBS 
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containing 0.1% gelatin) and a coating buffer (50 mM carbonate, pH 9.6) 
for ELISA. 
 
6.1 .3 Equipment 
 
The microscopes used were an Olympus BX10 fluorescence microscope 
(Olympus Optical, Tokyo, Japan) and a laser scanning microscope LSM 510 
META (Zeiss, Jena, Germany). Flow cytometry was performed by a 
FACScan (Becton Dickinson, Heidelberg, Germany). The ELISA-reader used 
was from Spectramax, Molecular Devices, Munich, Germany. The Biacore 
2000 instrument and sensor chips were from Biacore AB, Uppsala, Sweden. 
Gammacounter was from Wallac, Turku, Finland. 
 
6.1 .4 Purified and recombinant proteins 
 
Plasma proteins FH and C3 were either purified and C3b generated as 
described (173, 234) or purchased from Calbiochem, La Jolla, CA, USA. 
C4b, C5 and factor I were from Calbiochem. Recombinant proteins FHL-1, 
FHR-3, FHR-4 and deletion mutants of FH were cloned, expressed in the 
baculovirus system and purified as described (185). C4BP was purified 
from plasma as described (74) or expressed using recombinant technology 
(39). Deletion mutants of C4BP were constructed and expressed as 
described and purified by affinity chromatography (37, 39).  
 
The expression and purification of the recombinant Borrelia burgdorferi 
sensu stricto surface proteins is decribed in detail elsewhere (5, 122, 
256). 
 
 
6.1 .5 Antibodies 
 
Primary antibodies used in the analyses are listed in Table 5. Secondary 
antibodies used were: Fluorescein isothiocyanate (FITC)-conjugated goat 
anti-mouse IgG (I, II) and FITC-conjugated rabbit anti-mouse IgG antibodies 
(Alexa 488) (I, II, IV) from Molecular Probes, Eugene, OR, USA. FITC-
conjugated goat anti-rabbit IgG (III), FITC-conjugated rabbit anti-mouse IgG 
(IV), horseradish peroxidase (HRP) -conjugated donkey anti-goat IgG 
antibodies (II) were from Santa Cruz Biotechnology, Santa Cruz, CA, USA. 
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Table 5. The primary antibodies used in the assays. The original 
publication where the antibody was used is marked on the right column. 
Details of the manufacturers: Behring and Calbiochem, La Jolla, CA, USA; 
Dako, Glostrup, Denmark ; DiaSorin, Stillwater, MN, USA; Quidel, San Diego, 
CA, USA; Sigma Chemical Co., St. Louis, MO, USA; The Binding Site, 
Birmingham, UK. Abbreviations used: mAb, monoclonal antibody; pAb, 
polyclonal antibody. 
 
Antibody Description Reference or source Used 
in  
196X mouse mAb against FH (161)/J. Tamerius, 
LaJolla, CA 
II 
AF1 mouse mAb against HF1 B-cell 
lymphoma 
M. Kaartinen, Helsinki, 
Finland 
I 
Anti-βIH goat pAb against βIH (FH) DiaSorin V 
Anti-C1q rabbit pAb against C1q Dako II 
Anti-C4BP sheep pAb against C4BP The Binding Site V 
Anti-C5 goat pAb against C5 Quidel  II 
Anti-C6 goat pAb against C6 Quidel  II 
Anti-CD11b mouse mAb against CD11b Sigma IV 
Anti-Crasp1 mouse mAb against CRASP-1 R. Wallich, Frankfurt, 
Germany 
II 
Anti-FH goat pAb against FH Calbiochem, La Jolla, 
CA 
II, III 
Anti-iC3b mouse mAb against iC3b 
neoepitope 
Quidel  I, II 
Anti-SC5b-9 mouse mAb against C5b-9 Quidel  II 
Anti-SCR1-4 rabbit pAb against FH SCR1-4 J. Hellwage, Jena, 
Germany 
III 
Anti-SCR19-
20 
rabbit pAb against FH SCR19-20 J. Hellwage III 
mAb140 mouse mAb against C4BP CCP1 (126)/B. Dahlbäck, 
Malmö, Sweden 
IV 
mAb70 mouse mAb against C4BP CCP1 (126)/ B. Dahlbäck IV 
VIG8 mouse mAb against FH SCR19-
20 
(253)/ W. Prodinger, 
Innsbruck, Austria 
I 
WU13/15 mouse mAb against C5b-9 
neoepitope 
R. Würzner, Innsbruck, 
Austria 
II 
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FITC-conjugated goat anti-rabbit IgG (II), HRP-conjugated rabbit anti-goat 
IgG (III), HRP-conjugated rabbit anti-mouse IgG (IV), HRP-conjugated 
donkey anti-goat IgG antibodies from Dako, Glostrup, Denmark. HRP-
conjugated rabbit anti-sheep IgG (V) was from Jackson Immunoresearch 
Laboratories, Cambridgeshire, UK. 
 
6.2 Microbiological methods 
 
6.2 .1 Borrelia burgdorferi sensu lato strains 
 
B. burgdorferi sensu stricto (strain Bbia) was isolated from the 
cerebrospinal fluid of a Finnish neuroborreliosis patient. B. afzelii (strains 
BaA91 and 1082) and B. garinii (strains 13, 28, 40, 46, 50) were isolated 
from skin biopsies of Finnish patients with erythema migrans. They were 
kind gifts from prof. Matti Viljanen (National Public Health Institute, Turku, 
Finland). The strains were identified to the species level by sequencing the 
polymerase chain reaction-amplified fragment of a flagellin gene (293). All 
strains were grown in BSK-H Complete medium at 33°C.  
 
6 .2 .2 Onchocerca volvulus microfilariae  
 
Nodules containing adult O. volvulus worms were prepared from patients in 
Guinea, West Africa, as described (7), and adult worms were isolated from 
the freshly collected nodules (280). Microfilariae (MF) were isolated 
directly from the female worms, transferred into RPMI1640 medium 
supplemented with L-glutamine, penicillin and streptomycin and 
immediately frozen with liquid nitrogen. For measuring C activation by the 
MF (C3a and TCC ELISA-assays) they were pretreated with trypsin (3 
mg/ml at +37°C for 45 min). The activity of trypsin was stopped by 
soybean trypsin inhibitor (6 mg/ml). MF were washed 5 times with RPMI 
before incubation in 50% NHS for 15 minutes at +37°C. C activation was 
stopped by adding EDTA to a final concentration of 10 mM. All samples 
were centrifuged and the supernatants were frozen to -20°C. 
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6.2 .3 Strains of Candidae and Saccharomyces  
 
C. albicans (strains SC5314 (106), ATCC18804 and EBP), C. glabrata, C. 
krusei, C. tropicalis, C. parapsilosis and Saccharomyces cerevisiae (strain 
SEY6210) were grown at +28°C on yeast-peptone-dextrose medium (2% 
glucose, 2% peptone, 1% yeast extract) or on Saboraud agar. Hyphal 
growth was induced by a further incubation for 90 min at 37 0C in RPMI 
supplemented with 25 mM HEPES and L-glutamine or by incubating the 
cells at +37°C for 120 min. 
 
6 .2 .4 Borrelia recurrentis and B. duttonii strains 
 
Strains of Borrelia recurrentis (A5, A6, A11, A17) and Borrelia duttonii (La, 
Ku, Kw) were isolated from relapsing fever patients in Ethiopia and 
Tanzania as described (69). Strains were grown at +33°C in BSK-H 
Complete medium. 
 
6.3 Immunological methods  
 
Immunological methods used in each original publication are listed in Table 
6 and described here on a general basis. 
 
6.3 .1 Cell absorption assay 
 
Microbes were incubated in NHS, NHS-EDTA or with purified proteins. After 
washing the microbes five times the proteins bound to their surfaces were 
eluted with an acidic buffer (0.2 M glycine-HCl, pH 2.0) and the 
supernatants were collected. Samples of the wash and elute fractions were 
subjected to sodium-dodecyl-sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred onto nitrocellulose membranes. Bound 
proteins were detected by a primary antibody and a HRP-conjugated 
secondary antibody, which was detected by enhanced chemiluminescence 
(ECL). 
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Table 6 . Methods used in individual studies.  
 
Method Publication 
Cell absorption assay III, IV, V 
Cell adhesion assay IV 
Cofactor-assay  II, III, IV, V 
Enzyme-linked immunosorbent assay II, IV 
Flow cytometry III, IV 
Immunofluorescence microscopy I, II, III, IV 
Protein binding assay I, II, III, IV, V 
Serum sensitivity assay I, V 
Surface plasmon resonance (Biacore) I 
 
6.3 .2 Cell adhesion assay 
 
Approximately 105 HUVEC cells were seeded onto microtiter plates and 
cultivated for 48 h at 370C in a humidified 5% CO2 atmosphere in 
RPMI1640-medium. After washing with PBS, cells were cultivated in DMEM 
medium for an additional 24 h. C. albicans cells were added on top of the 
HUVEC-cells with or without purified C4BP. After incubation for 3 h at 370C 
C. albicans cells were stained with Calcofluor-stain (30 min at 37 0C), 
washed and the amount of the HUVEC-bound C. albicans-cells were 
determined using a fluorescence reader.  
 
6.3 .3 Cofactor assay 
 
Cofactor activities for C3b or C4b inactivation of surface attached C 
regulators FH or C4BP were measured after preincubating the microbes 
with NHS-EDTA or with purified C regulators for 120 min at +37°C. 
Bacteria were washed for three times and FI (50 ng/reaction) together 
with either 125I-C3b, 125I-C4b (approximately 50,000 cpm/assay) or biotin-
labeled C4b were added. The samples were further incubated for 60 min at 
+37°C. The samples were centrifuged and the supernatants were subjected 
to SDS-PAGE under reducing conditions to detect the cleavage of 125I-C3b 
or 125I-C4b. The gels were fixed with 5% acetic acid for 10 minutes and 
dried prior to autoradiography. The cleavage of the biotin-labeled C4b was 
detected by Western blotting. 
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6.3 .4 ELISA for detecting C3a and TCC  
 
For the C3a enzyme immunoassay samples were diluted into the 
manufacturers sample buffer and subjected to the ELISA assay according 
to the manufacturer's instructions.  
 
For the detection of TCC, MaxiSorp microtiter plates were coated overnight 
with a monoclonal antibody specific for the SC5b-9 neoepitope (5 µg/ml) 
in an ELISA coating buffer at +4°C for 12 hours. The wells were washed 
five times with PBS-T. The samples were diluted 1:200 and 1:1000 and 
aliquots of 100 µl were placed into the wells. After a 60 min incubation at 
+22°C the wells were washed for five times with PBS-T. A mixture of 
polyclonal goat anti-human C5 and anti-human C6 antibodies, diluted 
1:1000 in PBS-T, was added (100 µl/well) and the plates were incubated 
for 1 hour at +22°C. After washing the wells a peroxidase-conjugated 
secondary donkey anti-goat IgG antibody, diluted in PBS-T and 
supplemented with 1% normal mouse serum (100 µl/well), was incubated 
in the wells for 60 min at +22°C. After further washings the substrate, o-
phenyl-diamine diluted in H20 and supplemented with 0.04% H2O2, was 
added. After a 15 min incubation at +22°C the reaction was stopped by 
adding 50 µl of 2M H2SO4 per well. The absorbances were read with an 
ELISA-reader using a 492 nm filter. Purified SC5b-9 was used to set up the 
standard curve. 
 
6 .3 .5 ELISA for the binding assays with C. albicans  
 
Microtiter plates were coated for four hours with cells of C. albicans in 
RPMI1640 medium at +37°C to obtain the hyphal growth. Nonspecific 
binding sites were blocked with 2% BSA in PBS and proteins (C4BP, 
recombinant deletion mutants of C4BP) (10 µg/ml) in 1% BSA/PBS were 
added. In inhibition assays antibodies or proteins (10 µg/ml) were added to 
the reaction mixture. The proteins were allowed to bind at +37°C for 120 
min. After five washes with 1% BSA/PBS a monoclonal antibody (0.5 
µg/ml in 1% BSA/PBS;100 µl/well) was added and the plates were 
incubated for 60 min at +22°C. After five washes a peroxidase-conjugated 
secondary antibody (diluted 1:4000, 100 µl/well) was added. After 60 min 
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incubation in RT the substrate, o-phenyl-diamine diluted in H20 and 
supplemented with 0.04% H2O2, was added. The reaction was stopped and 
the result read as described above. 
 
6.3 .6 Flow cytometry and immunofluorescence microscopy  
 
The microbes were incubated in NHS, NHS-EDTA or with the purified C 
regulator using optimized incubation times and temperatures according to 
the microbe used. After washing the samples for three times, nonspecific 
binding sites were blocked (Candida albicans) by incubating the samples 
with 1% fat free milk or 1% BSA. Primary antibodies were added and the 
mixtures were incubated for variable times (30 min with Borrelia 12 hours 
with C. albicans) and washed for three times. Secondary FITC-labeled 
antibodies (diluted 1:200) were incubated with the samples for 30 min 
(Borrelia), 45 min (MF) or 60 min (C. albicans) at +22°C. After washing the 
samples for three times the microbes were mounted with mounting media 
and microscoped using a fluorescence microscope or subjected to flow 
cytometry. 
 
6.3 .7 Protein binding assay 
 
The C regulators, their recombinant fragments or BSA were radiolabeled 
with 125Iodine using the Iodogen-method as described (275). The indicated 
amounts of microbes were incubated with the labeled proteins 
(approximately 40,000 - 60,000 cpm/tube) in GVB or 1/3 GVB for 30°C 
at +37°C. The bound protein was separated from the unbound by 
centrifuging the samples through 20% sucrose. The supernatant and the 
pellet were subjected to γ-counting and the amount of bound protein was 
calculated as a percentage of pellet vs. total radioactivity in the pellet plus 
supernatant. Inhibitory effects of the same or other unlabeled proteins 
were analyzed by adding the indicated amounts of the unlabeled proteins 
to the reaction mixtures before the radioactive one. 
 
6.3 .8 Serum sensitivity assay 
 
Freshly harvested Borreliae (1x106) were washed for three times with VBS. 
Cells were incubated with 70% NHS in serum free BSK-H medium in a total 
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volume of 600 µl at +37°C on a shaker (500 rpm). As a control, the cells 
were incubated in the absence of NHS. After 1, 2, 3, 4, 5 and 24 hours 
aliquots of 20 µl were subcultured to 150 µl of BSK-H Complete medium 
and cultured at +33°C for three days. At each timepoint fresh serum (2% 
of the total reaction volume) was added. After cultivation the viability of 
the cells was evaluated microscopically under dark field. 
 
The effect of soluble OspE on the survival of B. burgdorferi in NHS was 
assayed with freshly harvested or frozen bacteria. The bacteria were 
washed with GVB and incubated for 2 hours at 37°C with either NHS-HI, 
NHS or NHS supplemented with 0, 20 or 200 µg/ml (final concentration) 
of soluble OspE protein. Serum was added after 30 and 60 min to avoid 
depletion of the C components caused by blocking of FH. The final serum 
concentration shifted from 20 to 33% during the experiment. The 
surviving bacteria were counted microscopically after 2 hours, and the 
percentage of alive spirochetes was calculated. 
 
6.3 .9 Surface plasmon resonance assay 
 
Protein-protein interactions were analyzed in real time by the surface 
plasmon resonance technique using the Biacore 2000 instrument. 
Proteins were immobilized via a standard amine-coupling procedure to 
flowcells of a sensor chip. Flowcells were activated with the mixture of 
35 µl NHS-EDC. The protein to be immobilized was dialyzed against 20 
mM acetate buffer (pH 4.8 – 5.5) and 20 µg portions (>150 µg/ml) of 
the proteins were injected into one of the flowcells. A flowcell without 
any protein was used as a control. Unreacted groups in the flowcells were 
inactivated by a ethanolamine-HCl injection (35 µl). After the coupling 
procedure, the flowcells were washed thoroughly with sequential 
injections of 1/3 VBS (pH 7.4), and 3 M NaCl in 10 mM acetate buffer 
(pH 4.6). Binding proteins were dialyzed against 1/3 VBS and protein 
concentrations were measured usingthe BCA protein assay. Each ligand 
was injected separately to a blank control flowcell and to a coated 
flowcell using a flow rate of 5 µl/min at +22°C. The final concentrations 
of the fluid-phase ligands in the binding assay ranged from 125 to 200 
µg/ml. 
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7 RESULTS 
 
7.1 Borrelia burgdorferi sensu lato (I) 
 
Three different genospecies in the group B. burgdorferi sensu lato are 
human pathogens: B. burgdorferi sensu stricto, B. afzelii and B. garinii. It 
has previously been shown that B. burgdorferi sensu stricto and B. afzelii 
are more resistant to human C than B. garinii (44, 187). We wanted to 
examine, if differences in the C-mediated serum sensitivity among borrelial 
genospecies could be due to the utilization of the AP fluid phase 
regulators.  
 
First we tested binding of FH from non-immune NHS and NHS-EDTA to 
Borreliae by immunofluorescence (IFL)-microscopy. We saw clear 
deposition of FH on the surfaces of the C-resistant B. burgdorferi sensu 
stricto and B. afzelii, and a weaker deposition on the C-sensitive B. garinii. 
When C activation in NHS was blocked with EDTA, the result was the same, 
indicating that binding of FH to the borrelia occurred also independently of 
C3b deposition on the cells. Binding of FH and FHL-1 to the bacteria in the 
absence of serum was tested further using a direct binding assay with 
purified and 125I-labeled FH and FHL. Binding of FH to the B. burdorferi 
sensu stricto strain was strong (up to 8% of the total radioactivity) and to 
the strains of the serum sensitive B. garinii it varied between 1-2%. 125I-
FHL bound to the B. burgdorferi sensu stricto (5% binding), but not to B. 
garinii (approximately 1% ). Binding of FH and FHL-1 to different 
genospecies of borrelia correlated with the sensitivity to C-mediated killing; 
the resistant strain bound the regulators and the sensitive did not.  
 
Next we aimed at identifying a ligand for FH by testing a selection of B. 
burgdorferi sensu stricto major outer surface proteins (P35/BBK32, OspA 
(outer surface protein A), OspC, OspD, OspE and DbpA) using the surface 
plasmon resonance. FH was coupled to the sensor chip by the standard 
amine coupling method and the borrelial proteins were applied to the fluid 
phase. The only protein that bound to FH was OspE. The same result was 
obtained on a turned setup where OspE was coupled to the sensor chip 
and FH was in the fluid phase. No direct interaction between OspE and C3b 
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or C5 was observed. The specificity of the interaction was confirmed in a 
binding assay where soluble OspE inhibited the binding of 125I-FH to the 
bacteria in a dose-dependent manner. According to the these results OspE 
was recognized as the first specific ligand for FH in B. burgdorferi sensu 
stricto. 
 
To evaluate the role of FH acquisition in the serum resistance of borreliae 
we analyzed the effect of soluble OspE on the survival of the three 
genospecies in NHS in the presence of OspE. Introduction of OspE (200 
µg/ml) resulted in a significantly decreased survival of B. burgdorferi sensu 
stricto (90% vs. 5% ) and B. garinii (20% vs. 1% ). B. afzelii was not 
affected by NHS or the addition of OspE. We concluded, that OspE-
mediated binding of FH to the B. burgdorferi sensu stricto is a very 
important mediator of serum resistance and therefore a clear survival 
factor.  
 
The binding site of OspE for FH was located to the C-terminal SCRs 15-20 
using recombinant constructs of FH (SCR1-7, 8-20 and 15-20) and the 
Biacore method.  
 
7.2 Onchocerca volvulus (II) 
 
Microfilariae of O. volvulus, the causative agent of river blindness, can 
survive in tissues of the human host for up to two years. Opsonization by 
C has been shown to be important for the phagocytosis of mf of other 
species of parasitic nematode species. We were interested in seeing 
whether mf of O. volvulus can utilize the AP regulator FH for their 
protection against C attack and evasion from phagocytosis.  
 
As there were no published studies available about the C sensitivity of O. 
volvulus, we first tested, whether mf activate the C system or not. When 
mf of O. volvulus were incubated in non-immune NHS detectable, although 
minor, C activation took place. In this experiment some amount of C3a, the 
anaphylatoxin which is cleaved from C3 during the C activation, was 
formed. When trypsin was used to remove polypeptides from the surface 
of mf, formation of C3a reduced. When the amount of TCC was measured 
after the exposure to NHS no TCC generation could be observed indicating 
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that C activation was restricted on the mf surface. Trypsin treatment, 
however, increased the generation of TCC about two-fold. 
 
Next we analyzed depositions of iC3b and C5b-9 on the mf after their 
exposure to non-immune NHS. iC3b, but no deposition of the terminal 
complex C5b-9, could be detected. We concluded that on the surface of 
mf AP was activated to some extent, but the formed C3b was quickly 
inactivated to iC3b and no TP activation nor formation of TCC took place.  
 
Using IFL microscopy we observed that mf bound FH. Binding was verified 
using purified 125I-labeled FH and recombinant proteins in direct binding 
assays and the mediator site was located to C-terminal SCRs 8-20. 
 
The functional activity of the serum acquired host C regulator was tested 
in a cofactor assay. Mf were preincubated in non-immune NHS, washed and 
incubated with 125I-C3b together with factor I. As a result, FH became 
bound to the mf and had maintained its cofactor-activity for inactivation 
C3b. We concluded that acquisition of soluble FH from serum contributed 
to the C resistance and survival of mf in human tissues.  
 
7.3 Candida albicans (III, IV) 
 
In further comparison between different types of microbes we next tested 
C. albicans. C. albicans activates all three pathways of C to some extent 
(179) and causes high numbers of invasive infections, especially in 
patients with deficiencies in acquired cell-mediated immunity. This 
suggests that the pathogenic strains have the ability to escape from the 
opsonizing effects of C.  
 
Binding of FH, FHL-1 and C4BP to the cells and hyphal forms of C. albicans 
was assayed in a serum-bathing assay, by IFL-staining, flow cytometry, 
direct binding assays and ELISA. In a serum bathing assay FH and FHL-1 
were detected on the cellular forms, while C4BP bound both to the cellular 
forms and hyphae. The localization of C regulators on the surface on C. 
albicans was further assayed using IFL-staining and confocal microscopy. 
FH and FHL-1 bound evenly to the cell surface, while C4BP had a patchy 
distribution and bound more clearly to the tips of the hyphae. The bound 
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regulators were quantified using flow cytometry and binding was shown to 
be dose-dependent.  
 
The specificities of FH and C4BP binding were assayed in direct binding 
assays with 125I-FH or 125I-C4BP, where increasing amounts of unlabeled 
protein were added. The binding of both labeled proteins were found to be 
inhibited in a dose-dependent manner. Dose-dependency of the binding of 
C4BP to the hyphal forms was confirmed by ELISA. 
 
Using recombinantly expressed constructs we identified two sites on FH 
that mediate binding to C. albicans. The first is in SCR7, which is also the 
binding site in FHL-1, and the second is in the C-terminal SCRs 19-20. The 
binding sites were confirmed, when we observed that heparin, which binds 
to FH via the same SCRs, inhibited the binding of FH to C. albicans. The 
binding site on C4BP for Candida was localized to the SCRs 1-2 of the α-
chain using deletion mutants of C4BP in the ELISA assay.  
 
7.4 Relapsing fever borreliae (V) 
 
Relapsing fever borreliae can obviously survive in direct contact with the 
human plasma for long periods, as they cause a septic disease with 
relapses. We compared their serum-sensitivity with B. burgdorferi sensu 
stricto and B. garinii strains. Both tested relapsing fever borreliae, B. 
recurrentis and B. duttonii, survived the 24-hour NHS exposure, while B. 
garinii was killed within 4 hours and B. burgdorferi sensu stricto within 5 
hours.  
 
Next we analyzed the binding of the C regulators FH and C4BP from non-
immune serum to six different strains of relapsing fever borrelia. Clear 
binding to all the strains was detected. The results were confirmed with 
the purified 125I-labeled proteins in direct binding assays. The amount of 
C4BP binding varied three-fold between the different strains and FH bound 
to all the studied strains with a lower intensity. Binding of C4BP to the 
relapsing fever borreliae was specific, as shown by using 125I-labeled C4BP 
and increasing concentrations of unlabeled C4BP in a binding assay. We 
concluded that the studied relapsing fever borreliae are able to bind C4BP 
specifically and binding occurs in the absence of serum. 
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Finally, we tested whether the Borrelia-bound C4BP and FH are still 
functional in downregulating the C activation. Borrelia that had been pre-
incubated with NHS possessed cofactor activity for FI-mediated cleavage 
of 125I-labeled C4b and C3b, while the spirochetes that had been pre-
incubated in buffer did not possess any cofactor activity. Similar results 
were obtained when the borreliae were pre-incubated with purified C4BP or 
FH instead of NHS. Thus, the C regulators are bound to the relapsing fever 
borreliae in such a way that they are able to contribute and even be 
responsible for the C resistance of the relapsing fever borreliae. 
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8 DISCUSSION 
 
8.1 Serum sensitivity 
 
Complement can lyse susceptible target cells by forming MAC-complexes 
on the cell membranes. Many microbes, especially pathogenic ones, are 
more or less well protected against the MAC-mediated lysis. Gram-positive 
bacteria are generally not susceptible to lysis due to the thick 
peptidoglycan layer around the cell membrane (Fig. 4). The same is true 
for smooth strains of Gram negative bacteria with long O-antigens, while 
the rough strains that have less or no O-antigens at all on LPS are usually 
more susceptible to serum-mediated killing (306). Yeasts and most 
multicellular parasites have a chitinous or tegumental surface structure, 
which can prevent lysis by MAC. For pathogenic microbes specific C 
evasion mechanisms are mainly needed for protection from C-mediated 
opsonization and phagocytosis. Some microbes, on the other hand, are 
susceptible to C-mediated lysis. For these microbes C is a double-edged 
sword since activation can lead to lysis as well as to opsonophagocytosis. 
Microbes, which are able to prevent C activation, are generally considered 
to be more virulent and cause more severe and invasive infections. As an 
example, patient-derived strains of Neisseria gonorrhoeae, which are able 
to cause disseminated infections, are usually serum-resistant, and strains 
causing localized symptomatic infections are serum-sensitive, when 
exposed to NHS in vitro (269).  
 
Complement is the only clearly microbicidal system in non-immune human 
plasma, although some other plasma constituents such as antimicrobial 
peptides can be found in patient sera during invasive infections. When non-
immune serum is used for analysis of serum sensitivity the analysis actually 
measures C-sensitivity. Serum sensitivities of the microbes examined in 
this thesis are different.  
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Gram-positive 
Gram-negative 
Borrelia 
inner membrane 
inner membrane 
inner membrane 
outer membrane 
outer membrane 
peptidoglycan 
peptidoglycan 
peptidoglycan 
periplasmic flagella 
lipopolysaccharide 
Fig. 4. Schematic structures of the cell walls of Gram positive bacteria,  
Gram negative bacteria and Borrelia. 
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It is well documented that two genospecies of B. burgdorferi sensu lato, B. 
burgdorferi sensu stricto and B. afzelii, are serum resistant, while B. garinii 
is serum sensitive. These differences are known to be C-dependent (12, 
44, 187). For relapsing fever borreliae no such data existed. Therefore, we 
compared the serum-sensitivities of these borreliae with B. burgdorferi 
sensu stricto and B. garinii (I). Relapsing fever agents are able to persist in 
the human circulation for weeks. Thus, it was not a surprise that they were 
even more resistant to serum C than B. burgdorferi sensu stricto. By 
adding fresh serum we prevented depletion of C activity during the 
prolonged incubation, but still both of the tested relapsing fever borreliae 
tolerated non-immune NHS for at least 24 hours (V). Serum C can kill the 
serum-sensitive genospecies B. garinii by the lytic activity of the MAC, but 
it was not known, if the relapsing fever borreliae could be lysed. In general 
due to structural similarities between the different spirochetes it is likely 
that MAC complexes would lyse also the relapsing fever borreliae if C was 
not regulated on their surfaces. 
 
Onchocerca volvulus mf circulate in the host for up to two years, but 
mainly in the subcutaneous tissues, skin and eyes. At least the extracellular 
fluid in subcutaneous tissue contains all the essential components for C 
activation and MAC-formation. We observed that mf activate C to the C3-
level, as during the incubation in serum C3 was cleaved to C3a and C3b. 
This formed C3b was, however, quickly turned into iC3b, and no detectable 
TCC formation took place. We thus concluded that mf are obviously serum 
resistant (II). 
 
Candida albicans is known to efficiently activate C, even via all the three 
pathways (180, 181). It is also known that C. albicans is resistant to the 
lytic effect of serum, as cells can be in direct contact with serum for many 
hours and still be viable. The TP of C is ineffective in lysing C. albicans, 
probably because of the rigid chitinous cell wall structure. But the 
opsonizing effect of C affects the survival of C. albicans in vivo, and thus C 
evasion is supposed to be important for the virulence of C. albicans.  
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8.2 Acquisition of FH and FHL-1  
 
In this work FH was shown to bind all the microbes studied. On the basis of 
the current and several other studies it can be concluded that FH is bound 
directly and specifically to the microbial surfaces, and no other serum 
component mediates the interaction. FHL-1 was found to bind to Candida 
albicans, Borrelia burgdorferi sensu stricto and to two relapsing fever 
borrelia (I, III, IV).  
 
From the microbes studied, we were able to identify one ligand for FH. This 
was the outer surface protein E (OspE) of B. burgdorferi sensu stricto. 
None of the other tested surface proteins of borrelia (OspA, OspC, OspD, 
fibronectin binding protein P35 and decorin-binding protein DbpA) bound 
FH. OspE belongs to a group OspE paralogs, which are encoded by a gene 
in a circular plasmid and coexpressed with OspF (189). These proteins are 
also called Erps (OspEF-related proteins) (189). Expression of OspE is 
upregulated by a temperature shift from 23° to 35°C, i.e. in circumstances 
that the spirochetes meet while entering the human host (297). After our 
original discovery more data on the interaction between OspE and FH has 
been published. The C-terminus of OspE and its three-dimensional coiled-
coil structure are important in binding of FH (10, 11, 202, 211). Another 
FH -binding protein from this family was called BbCRASP-3 (183). Later 
another type of ligand for FH, BbCRASP-1 (also named as Bba68) was 
cloned (107, 182). The crystal structure of BbCRASP-1/Bba68 revealed a 
protein with several α-helixes (63, 64). Serum resistant Borrelia afzelii also 
expresses a FH-binding protein (317). According to our own findings 
(Alitalo et. al, unpublished data) patient-derived strains of B. garinii bind FH 
too, but the binding is lost upon cultivation in vitro. In the Lyme disease 
borreliae binding of FH and/or FHL-1 has been shown to be a very 
important determinant of pathogenicity. Furthermore, multiple ligands for 
the C regulators highlight the importance of C evasion for the bacteria. 
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Relapsing fever borreliae are also able to bind FH, which has been shown by 
us (210), in V and by others (201). McDowell et. al detected a 20 kD FH-
binding protein in B. hermsii and B. parkerii by an affinity ligand test (201). 
Hovis et. al identified the ligand in B. hermsii for FH as a linear-plasmid 
encoced protein, which is not homologous to any other FH -binding protein 
of borreliae known to date. Interestingly, the sequence of this protein was 
not found from the genome of B. parkeri. (142). We used several strains of 
the only species causing LBRF, B. recurrentis, and several strains of species 
causing TBRF, B. duttonii, in direct binding assays and serum-bathing 
assays and saw binding of FH to these borreliae too.  
 
Interestingly many microbes bind FH via the same SCRs, that are important 
in target recognition by FH (Fig. 5). SCR7 and SCR20 contain heparin 
binding sites (32, 33) and the C-terminal SCRs 19-20 mediated binding of 
FH to C. albicans and to OspE of Borrelia burgdorferi sensu stricto. Another 
binding site on FH and FHL-1 to C. albicans was localized to SCR7, which 
has previously been shown to mediate binding of FH to M-proteins of group 
A streptococci (31, 177). Furthermore, the binding sites on SCR7 the for 
heparin and M protein seem to be overlapping (114). Since SCR7 is 
common for FH and FHL-1 a microbe, that binds to SCR7, is able to acquire 
both the regulators to its surface, like CRASP-1 of B. burgdorferi sensu 
stricto does (182). When binding is mediated via SCR7 or more C-terminal 
region, the functional SCRs 1-4 are free for exhibiting the C regulatory 
activity. During evolution it might have been more beneficial for a microbe  
N C 
M Protein (Group A Streptococcus) 
OspE (Borrelia burgdorferi) 
Hic (Streptococcus pneumoniae)  
LOS (Neisseria gonorrhoeae) 
 
Candida 
albicans 
Candida 
albicans 
Fig. 5. Some microbial interactions sites in FH 
CRASP-1 (Borrelia burgdorferi) 
β (Group B Streptococcus) 
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Table 7. Microbes that have been reported to bind the C regulator FH. The 
main ligand, if known, and the key references are given. 
 
Microbe Ligand for FH Main reference 
  
Gram-positive cocci 
  
 Streptococcus pyogenes M-protein 
Fba 
(140) 
(228) 
Streptococcus pneumoniae PspC 
Hic 
(217) 
(148) 
Staphylococcus aureus ? (153) 
   
 
Gram-negative cocci 
  
Neisseria gonorrhoeae Porin 
LOS 
(260)  
(261) 
N. meningitidis LOS (259) 
   
 
 
Gram-negative bacilli 
  
Yersinia enterocolitica YadA (55) 
Pseudomonas aeruginosa ? (143) 
   
 
Spirochetes 
  
Borrelia burgdorferi s.l. OspE/CRASP-3 
CRASP1/Bba68 
(I)/(183) 
(182) 
Relapsing fever borrelia ? (V) 
Leptospires ?  Meri et. al, 
unpublished 
   
 
Yeasts 
  
Candida albicans ? (III) 
Cryptococcus neoformans ? (274) 
   
 
Helminths 
  
Echinococcus granulosus ?  (84) 
Onchocerca volvulus ? (II) 
Nippostrg. brasiliensis ? (16) 
Loa Loa ? Haapasalo et. 
al, unpublished 
   
Viruses   
HIV 
 
gp41, gp120 (245,246) 
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to use such a host structure, that is very important also for the host and 
therefore less likely to be mutated. 
 
C. albicans has been reported to have complement receptor-like surface 
molecules which were suggested to bind C3d or iC3b (6, 131) and be 
virulence factors (226). The human complement receptor 3 
(CR3;CD11b/18) expressed on neutrophils has been suggested to be a 
receptor for factor H (87). It might be speculated that the C. albicans CR3-
like protein may actually be the ligand for FH and FHL-1, but this 
hypothesis remains to be tested. 
 
Microbes, which have been suggested to bind FH, are listed in Table 7. 
Many interactions have been well characterized, and mutations made on 
the ligands have been shown to affect the binding and survival of the 
microbe. On the other hand, some interactions might be nonspecific and 
due to general adhesion of FH to the microbes. 
 
8.3 Acquisition of C4BP 
 
Microbes that have been previously shown to bind C4BP, are listed in the 
Table 8. They are Gram negative or positive cocci or Gram negative bacilli. 
In this thesis two new groups of microbes, spirochetes and yeasts, are 
reported to able to acquire C4BP (IV, V).  
 
Evasion of the classical pathway is beneficial for both the microbes we 
have shown to bind C4BP. C. albicans can cause severe invasive infections, 
but it is also a harmless commensal found frequently on mucous 
membranes. Thus the naturally occuring antibodies against C. albicans are 
common and those antibodies can usually activate the CP (327). Mannan 
on the outer surface of the yeast activates the lectin pathway and binding 
of C4BP might protect C. albicans also from the lectin pathway.  
 
Relapsing fever borreliae are able to persists in human blood from several 
days to weeks. The best known immune evasion mechanism demonstrated 
for these borreliae is antigenic variation, i.e. ability to change the major 
outer surface proteins in cycles, leading to a persistence as a new 
“serotype” in the human host. The antigenic variation leads to changing of 
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only one type of a surface protein, while the other surface structures are 
not be changed. Therefore, the acquisition of C4BP onto the bacterial 
surface could reduce the antibody-dependent CP activation below a rate 
that is required for opsonization or propagation of the C activation to 
MAC-formation. Evasion of adaptive immunity by a combination of 
antigenic variation and C4BP acquisition might be needed for the long 
bacteremic and highly  lethal course of the disease. 
 
Also other microbes causing persistent infections, like Lyme disease and 
river blindness, have to protect themselves against antibodies, which are 
raised during the long existence in the human host. For these microbes 
evasion from CP might also be essential for survival and pathogenicity and 
it would be interesting to know if they can acquire C4BP too. 
 
Most of the studied microbes, Streptococcus pyogenes (35), Bordetella 
pertussis (28) and C. albicans (IV),  interact with C4BP via the N-terminal 
SCRs 1-2 of the α-chain. C4b and heparin have also binding sites in the 
SCR1-2 (138), but due to its multimeric nature, binding of C4BP via these 
SCR domains does not arrest the functional activity of the microbe-bound 
regulator.  
 
Localization of C4BP to the tips of the hyphae in C. albicans was an 
interesting finding, as the morphogensis is one of the major virulence 
factors of C. albicans and moreover, hyphal tips are considered very 
important in the tissue penetration. C. albicans is able to change its outer 
surface composition during morphogenesis and simultaneous upregulation 
of C4BP-binding structures might be beneficial.  
 
Acquisition of all three fluid phase regulators has previosly been shown 
occur only on S. pyogenes, that binds C4BP, FHL-1 and FH via the M-
proteins (177, 308). N. gonorrhoeae binds C4BP and FH via surface 
expressed porins 1A and 1B (258, 259). C. albicans and relapsing fever 
borrelia are able to acquire both FH and C4BP. C. albicans binds also FHL-1 
and some strains of relapsing fever borreliae seen to acquire also FHL-1 or 
FHR-1 from human serum. The ligands for FH, FHL-1 and C4BP binding on 
C. albicans and relapsing fever borrelia remain to be discovered. But in the 
competition assay FHL-1, but not FH, inhibited binding of C4BP to the 
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cellular forms of C. albicans. This might imply that both the regulators are 
bound to the same structure on the surface of C. albicans. This seems 
possible and logical, as the regulators are structurally related, but unlikely, 
as simultaneous evasion from both AP and CP should be beneficial for the 
microbe. For example, in group A streptococcus, FHL-1 and C4BP have 
been shown to use different ligands on the same strain (237). 
 
Table 8. Microbes reported to bind the C regulator C4BP. The main ligand, 
if known, and the key reference are given. 
 
Microbe Ligand for C4BP Main reference 
  
Gram-positive cocci 
  
 Streptococcus pyogenes Sir, Arp 
Enn18 
(308) 
(237) 
   
 
Gram-negative cocci 
  
  N.gonorrhoeae 
 
Porin 
type IV pili 
(258) 
(38) 
N. meningitidis PorA (151) 
Moraxella catarrhalis UspA1, UspA2 (224) 
 
Gram-negative bacilli 
  
E. coli OmpA (250) 
Bordetella pertussis FHA (26)  
 
Spirochetes 
  
B. recurrentis, B. duttonii ? (V) 
   
 
Yeasts 
  
Candida albicans ? (IV) 
   
 
Parasites 
  
Schistosoma mansoni 
Loa Loa 
? 
? 
Meri et. al., 
unpublished 
Haapasalo et. al, 
unpublished 
    
 
8.4 Functions of the surface-acquired regulators 
 
Surface-bound FH was shown to be functionally active on the surface of O. 
volvulus, C. albicans and relapsing fever borrelia as it acted as a cofactor in 
FI-mediated cleavage of C3b. In the absence of FH no cleavage occurred. 
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C. albicans has been reported to have a protease able to cleave C3 (164), 
but in our assay C. albicans cells without a contact with serum or purified 
FH were unable to cleave C3b. Also C4BP was functionally active in C4b 
cleavage, when bound to C. albicans and relapsing fever borrelia.  
 
It has been shown that in other bacteria, like in Streptococcus pyogenes, 
binding of FH and C4BP increases survival by directly interfering 
opsonophagocytosis (27, 140) and in Neisseria gonorrhoeae FH acquisition 
mediates serum sensitivity (260, 261).  
 
The importance of OspE in survival of B. burgdorferi sensu stricto was 
obvious in our serum sensitivity assay; when we blocked binding of FH to 
the borrelia by soluble OspE, the serum-mediated lysis of the spirochetes 
increased notably. On the basis of our results (I) soluble OspE makes the B. 
burgdorferi sensu stricto and B. garinii serum-sensitive indicating that it is 
a major mediator of FH-acquisition onto these microbes. The same has not 
been shown with the other identified FH ligands of Lyme disease borrelia.  
 
In addition to downregulation of C the attached C4BP seems to mediate or 
enhance adhesion of C. albicans to host endothelial cells. Adhesion is an 
important virulence factor of Candida during infections. Mediation of 
adherence is also a novel function for C4BP. As binding of C4BP was 
located to the tips of the hyphae, it might increase the virulence of C. 
albicans in two ways, in evasion of C and in adhesion.  
 
8.5 Conclusions  
 
Binding of FH and C4bp arrests C activation at the C3/C5 convertase level, 
thus preventing the attachment of opsonins to the microbial surface as 
well as progression of the C activation to the formation of MAC. Escape 
from opsonization is obviously important for microbial virulence. We have 
shown that very different microbes utilize fluid phase C regulators. Most 
probably the acquisition of the regulators increases survival of these 
microbes in blood or tissues and therefore contributes to the virulence 
 
In these studies we show, that B. burdorferi sensu stricto binds FH via 
OspE. Binding of FH increases the survival of bacteria when in contact with 
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human serum. Relapsing fever borrelia are able to bind both FH and C4BP is 
a manner which enables the bound regulators to maintain their regulatory 
functions. C. albicans is able to bind FH, FHL-1 and C4BP in a functionally 
active form. Mf of O. volvulus bind FH enabling inactivation of surface-
bound C3b. 
 
8.6 Future prospects 
 
On the basis of the reports from our laboratory and other groups it is 
evident that FH and/or C4BP acquisition is somewhat usual among 
pathogenic microbes. How binding of C regulators affects the virulence and 
survival of microbes is a very interesting question, which has been 
addressed with some microbes, but still not so many examples exist. For in 
vitro analysis we need to identify the ligands for binding of the C 
regulators and after inactivating them one by one to detect possible 
changes in serum sensitivity and/or susceptibility to phagocytosis. In vivo 
animal models, possibly with the available C regulator-deficient animals, is a 
prerequisite for assaying the real importance of the acquisition of FH and 
C4BP and necessary for the evaluation of the potential that the ligands 
might possess in vaccine development. 
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